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ABSTRACT OF DISSERTATION 
 
 
 
 
PREDICTORS OF READINESS TO INITIATE INSULIN THERAPY  
IN PATIENTS WITH TYPE 2 DIABETES WHEN ORAL  
MEDICATIONS FAIL TO CONTROL HYPERGLYCEMIA 
 
Type 2 diabetes (T2DM) has reached epidemic levels worldwide during the past two 
decades. It affects nearly 26 million adults in the U.S. Advances in both the treatments 
for T2DM and guidelines for its optimal management are extensive. Despite these 
advances, barely half of type 2 diabetics achieve recommended glycemic targets.  
 
Specific Aims: 
 
The specific aims were to: 
1. Describe the available research on clinical inertia and interventions that have been 
implemented to reduce it. 
2. Analyze various behavioral theories that explain and predict self-care practices in 
diabetes in order to develop a conceptual model on which to base an investigation of 
predictors of readiness to initiate insulin therapy in type 2 diabetics. 
3. Determine predictors of readiness to initiate insulin therapy in patients with T2DM 
when oral medications fail to control hyperglycemia using the conceptual model 
based on Self-Determination Theory (SDT) as a framework. 
 
Results: 
  
 A review of research articles published from 1990 to 2010 concluded that clinical 
inertia of primary care providers treating T2DM resulted in a majority of patients 
experiencing unnecessary chronic uncontrolled hyperglycemia. Behavioral theories were 
analyzed for their ability to predict self-care behaviors in type 2 diabetics. A conceptual 
model was developed based on the major constructs of SDT in order to guide the design 
of study to investigate predictors of readiness to begin insulin therapy in T2DM. Finally, 
a descriptive, correlational study was performed to determine readiness to initiate insulin 
therapy in patients with T2DM when oral medications fail to control hyperglycemia. 
 Results of the study revealed that participants who had a friend or family using insulin 
were 5.5 times more likely to rate their readiness to initiate insulin as high than those who 
had neither (p=.020). In addition, those with greater negative beliefs and attitudes toward 
insulin therapy were more likely to rate their readiness to initiate insulin as low (p=.012). 
A majority (58%) of participants rated their readiness to begin insulin therapy as 
immediate if it would give them better control over their hyperglycemia. The study also 
confirmed findings from previous studies that clinical inertia was present in this setting.  
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CHAPTER ONE 
Introduction 
 This year, the United Nations General Assembly recently convened the inaugural 
Summit on Non-communicable Diseases (NCD) which met in September 2011 in New 
York City (Beaglehole, Bonita, Horton, Adams, Alleyne, et al., 2011). The goal of the 
summit was two-fold: to increase awareness of NCDs and to reach common ground 
among heads of states and governments on directed efforts to prevent and control 
cardiovascular diseases, cancers., chronic respiratory diseases, and diabetes. Initially 
linked to rapidly changing lifestyles and urbanization in high-income countries, these 
diseases have now reached epidemic levels in middle- and low-income nations as 
emerging nations struggle with highly fluid population dynamics and increased 
urbanization (Probst-Hensch, Tanner, Kessler, Burri & Künzli, 2011). A case in point, 
India now accounts for nearly one-third of the global type 2 diabetes (T2DM) burden, 
with diabetes incidence continuing to increase at an alarming rate (Beaglehole et al.). 
Global prevalence of diabetes is projected to rise from the current 6.4% of the world’s 
population in 2010 to 7.8% of the world’s population by 2030 (World Diabetes 
Foundation, 2011). Some believe its prevalence worldwide may actually be higher by 
2030 in light of current trends (Probst-Hensch et al., 2011). 
 Because NCDs heavily impact health-related quality of life (HRQOL) of the 
individuals affected by them and jeopardize the socioeconomic productivity of 
populations, they have become the focus of researchers worldwide (Probst-Hensch et al., 
2011; World Economic Forum, 2011). The human and economic benefits of preventing 
NCDs are enormous, but instituting preventative measures is perhaps, the greatest 
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challenge to nations, especially for low- and middle-income countries. Primary 
prevention presents a lower-cost alternative than the long term and expensive tertiary 
management of these diseases that currently pervades health care systems worldwide 
(Geneau, Stuckler, Stachenko, McKee, Ebrahim, et al., 2010). Low cost, effective 
solutions for prevention are readily available, but as Geneau et al. argue, the failure to 
respond is largely political, not technical.  
 In the U.S. the emphasis is primarily on treatment of NCDs with a 
disproportionate amount of limited health care dollars directed at treating, rather than 
preventing, NCDs (Harkness & DeMarco, 2011). Despite the emphasis on treatment of 
NCDs, health care providers in the U.S. have not effectively used the pharmaceutical 
resources and evidence-based guidelines to implement treatment of these diseases, 
particularly in the case of T2DM. The state of pharmaceutical science for treating T2DM 
and the dissemination of guidelines for optimal treatment of diabetes to prevent or slow 
the development of its numerous sequelae have never been better (American Diabetes 
Association [ADA], 2011; Kunt & Snoek, 2009; U.K. Prospective Diabetes Study 
[UKPDS] Group, 1998). In fact, many experts believe that improvements in the outcomes 
of T2DM will have less to do with new treatments, and everything to do with how 
effectively health care providers implement the current drugs, technology, and knowledge 
available (Barag, 2011; Brown, Nichols & Perry, 2004). 
Scope and Importance of the Diabetes Problem 
Prevalence 
  Current estimates place diabetes prevalence rates at 8.3% of the U.S. population, 
roughly 26 million Americans, which has increased from previous estimates of 7.8% of 
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the U.S. population in 2007 (National Diabetes Information Clearinghouse [NDIC], 
2011). Approximately 90-95% of diabetes cases are type 2. Sedentary lifestyles, poor 
diet, and increased obesity of the population have contributed to the increasing incidence 
and prevalence rates of type 2 diabetes (Cobble, 2009; Cornell, 2011). Once considered 
an adult-onset health problem, it is now increasingly being diagnosed in school-age 
children (NDIC). 
Cost 
 The human costs of diabetes are significant. Diabetes increases risk of stroke and 
death from heart disease to rates that are two to four times those of nondiabetics (NDIC, 
2011). Diabetes is also the leading cause of new cases of blindness, kidney disease, and 
nontraumatic lower limb amputations (NDIC). The morbidity associated with diabetes 
doubles the risk for depression in this population (Anderson, Freedland, Clouse & 
Lustman, 2001).       
 The burden of diabetes also presents a crisis in terms of health care costs, both 
direct and indirect. Direct medical expenditures were estimated to be $116 billion in 2007 
while indirect costs from disability, work loss, and premature death were an additional 
$58 billion (NDIC, 2011). Future costs have been projected to escalate significantly. By 
2034, diabetes-related healthcare costs are expected to reach an estimated $336 billion in 
direct expenditures (Huang, Basu, O’Grady & Capretta, 2009). Disability related to 
complications of diabetes also affects the nation’s productivity (Geneau et al., 2010). 
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Type 2 Diabetes 
Pathophysiology and Criteria for Diagnosis 
 Type 2 diabetes is a progressive disease affecting multiple organ systems within 
the human body (Cefalu, Gerich & LeRoith, 2004). It is strongly associated with obesity; 
obesity, in turn increases risk for cardiovascular disease, which is the major cause of 
morbidity and mortality in T2DM. Pathophysiologic changes that occur in T2DM are 
characterized by a progressive decline in pancreatic β-cell function, insulin resistance, 
lack of suppression of post-prandial glucagon secretion, and apoptosis of pancreatic β-
cells from sustained hyperglycemia (Cefalu et al., 2004; Cornell, 2011). Diabetes is best 
conceptualized and managed as a global vascular disease with treatment focused on 
reversing abnormal glucose levels, dyslipidemia, inflammatory endothelial dysfunction, 
and accelerated atherosclerosis (Mirza, 2007). The net effect of this approach is 
preventing, or at least delaying, common sequelae of T2DM which include myocardial 
infarction, hypertensive heart disease, retinopathy and blindness, kidney insufficiency 
and failure, neuropathy, and lower extremity amputations (Cefalu et al.; Cornell). 
 Current criteria for the diagnosis of diabetes should include one of the following 
ADA (2011) accepted tests: (1) glycosylated hemoglobin (HbA1c) ≥ 6.5%, (2) fasting 
plasma glucose ≥ 126 mg/dl with minimum fasting interval of eight hours, (3) an oral 
glucose tolerance test (OGTT) yielding a two-hour plasma glucose level ≥ 200 mg/dl 
following an initial glucose load containing  75grams of anhydrous glucose dissolved in 
water, or (4) a patient who exhibits classic signs of hyperglycemia or hyperglycemic 
crisis and a random plasma glucose ≥ 200 mg/dl. 
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Recommended Management   
 The most effective means of preventing or delaying complications of diabetes is 
for an individual to monitor blood glucose levels frequently (3 to 4 times daily) and to 
maintain consistent control of blood glucose levels (ADA, 2011: UKPDS, 1998). 
Glycemic control should be monitored daily by the patient using finger-stick blood 
glucose testing. Diabetes clinicians assess long-term glycemic control by monitoring 
serial serum glycosylated hemoglobin levels (HbA1c); typically drawn every three 
months in patients who are not meeting glycemic goals or every six months in patients 
who are well controlled, in order to assess the effect of patients’ lifestyle changes and  
medically prescribed interventions (ADA; Cefalu et al., 2004). Optimal benefit and 
increased likelihood of preventing complications from T2DM are seen when patients’ 
HbA1c values are maintained below 7%. However, barely one-half of people with T2DM 
maintain their HbA1c at goal (Cobble, 2009). 
 Generally, clinicians follow a stepped-approach to treating new-onset T2DM, 
beginning with nonpharmacologic interventions such as dietary changes, weight loss, and 
increased physical activity (Cefalu et al., 2004). Oral medications are instituted when 
lifestyle modifications have not proven successful for keeping HbA1c at goal. Frequently 
a single oral agent is trialed initially and additional oral medications are added as 
tolerated based on HbA1c values. In many circumstances, insulin therapy is often 
reserved as a last resort by many clinicians when lifestyle modifications and multiple oral 
agents have failed to control hyperglycemia; a treatment practice that patients often 
equate with personal failure on their part to control their T2DM, worsening of their 
disease, or both (Cobble, 2009; Reach, 2008).  
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 More aggressive intensification of diabetes therapy has been advocated earlier in 
the course of the disease because experts contend that T2DM has likely been present for 
years, maybe even a decade, before it is formally diagnosed due to the asymptomatic 
nature of the illness in its early stages (Barag, 2011; Cobble; Dewitt & Hirsch, 2003). 
Unnecessarily delaying intensification of treatment regimens or delaying initiation of 
non-oral therapeutic agents in type 2 diabetics who have poor control of their 
hyperglycemia in early stages of disease will result in increased morbidity, and possibly 
premature mortality (Brown et al., 2004).  
 Up to 60% of type 2 diabetic patients will require insulin within six to ten years or 
perhaps sooner if they have experienced long-standing disease prior to diagnosis (Barag, 
2011). Recently, newer non-insulin injectable medications have been developed and are 
being more widely used with type 2 diabetic patients who are unable to maintain HbA1c 
at goal on multiple oral agents (Hinnen, Nielsen, Waninger & Kushner, 2006). These new 
drugs show promise in their ability to bring hyperglycemia under control and may 
possibly halt pancreatic β-cell destruction. 
Problems with Current Management of Diabetes Care 
 Increasing numbers of people with T2DM will experience disability related to 
their illness if the current paradigm of diabetes care does not change. Once considered the 
domain of diabetes specialists and endocrinologists, the medical management of T2DM 
continues to expand into the realm of primary care (Barag, 2011; Harris, Kapor, Lank, 
Willan & Houston, 2010). Patients were often referred to specialists who initiated and 
managed their insulin therapy. Now primary care physicians are far more likely to initiate 
and adjust patients’ insulin as they assume more responsibility for management of 
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patients’ diabetes care. This shift in management responsibility for the care of patients 
with diabetes presupposes that primary care clinicians feel competent and knowledgeable 
in managing T2DM, when in fact, many of them have demonstrated or admitted they are 
neither (Harris et al., 2010; Kunt & Snoek, 2009; Peyrot et al., 2005; Wallace & 
Matthews, 2000).  
 The paradigm shift in medicine over the last few decades, from an infectious 
disease model focused on eradicating disease to a model that focuses on managing 
chronic illnesses, also contributes to the under-treatment of many chronic illnesses and 
the frequent failure of care in type 2 diabetes. Failure of care in diabetes results from 
multiple factors. These factors include discordance between patient and provider goals, 
failure to communicate effectively, lack of adherence to current guidelines for treatment 
of T2DM, patients’ refusal to engage effectively in diabetes self-care practices, and lack 
of knowledge on the part of patients and health care providers (Reach, 2008).  
 Diabetes care requires a great deal of continuous participation from the patient in 
order to maintain effective glycemic control. Experts contend that people with diabetes 
provide about 95% of their own care (Anderson et al., 1995). Diabetics are involved in a 
constant struggle to maintain normal blood glucose levels. Self-management remains the 
cornerstone of T2DM care and it is believed by researchers that improving patient self-
efficacy is a crucial factor for improving patient outcomes (Lorig & Holman, 2003; 
Sarkar, Fisher & Schillinger, 2006). It is therefore essential to foster autonomy and 
confidence in patients to perform diabetes self-care, particularly self-care related to 
insulin therapy. Many experts agree that insulin is the most powerful and effective 
pharmacologic tool available to treat hyperglycemia and it will eventually be a necessary 
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component of treatment for effective control of blood glucose in a substantial number of 
patients with T2DM in reaction to β-cell failure as a natural course of the disease 
(Cobble, 2009; Riddle, 2002).  
 Clinicians are charged with the responsibility of initiating insulin therapy in a 
timely manner when indicated by the patient’s illness status (ADA, 2011; Cobble, 2009). 
Changing the way in which type 2 diabetics view insulin as part of their diabetes care is 
also part of that responsibility. The current diabetes care paradigm has failed in both 
respects thus far, which suggests that a shift in paradigms is warranted.  
Introduction to the Dissertation 
 This dissertation consists of three manuscripts found in Chapters Two through 
Four. Chapter Two of this dissertation presents an integrative review of the available 
research evidence exploring the reluctance of health care providers to initiate insulin 
therapy when indicated by chronic hyperglycemia in adult patients with type 2 diabetes, 
more recently termed clinical inertia. Specific aims of this literature review were: (1) to 
identify factors that have been shown to contribute to clinical inertia of primary care 
providers initiating insulin therapy in type 2 diabetes, (2) to identify strategies that have 
successfully decreased clinical inertia in primary care providers initiating insulin therapy 
in the care of type 2 diabetics, and (3) to identify individual-level strategies employed by 
primary care providers with type 2 diabetic patients to overcome clinical inertia and 
facilitate patient use of insulin therapy earlier in the disease course.  
 Multiple factors were found to contribute to clinical inertia. Common barriers 
such as nonadherence to published diabetes care guidelines, lack of knowledge regarding 
these guidelines, frustration with patients over real or perceived regimen nonadherence, 
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lack of time during visits with patients, competing needs in primary care, and 
misconceptions of providers’ perceptions of patient barriers to insulin therapy adoption 
were among the findings. 
 Studies evaluating healthcare system-level interventions and their effects on 
diabetes care and outcomes dominated the literature. Modest but significant 
improvements in HbA1c were realized by these interventions. However, HbA1c in all 
studies remained above the ADA (2011) recommended goal of < 7%. Individual-level 
intervention studies were not found. It was this latter finding that inspired the direction of 
the dissertation research. Recommendations for direction of future research in this area 
are discussed. 
 Chapter Three presents a critical analysis of several theoretical frameworks that 
have previously been used by researchers to explain and predict health and self-care 
behaviors in chronic illness, of which diabetes is one. The analysis was important for 
selection of the an appropriate theoretical framework on which to base an investigation of 
predictors of readiness for persons with type 2 diabetes who require transition to insulin 
therapy when oral medications have failed to control their hyperglycemia. No previous 
studies investigating insulin therapy readiness, and more specifically, none that used a 
behavioral theory framework were found; though a number of studies using behavioral 
theories to explain diabetics’ engagement in self-care practices and the effect of those 
practices on subsequent glycemic outcomes in T2DM are discussed.  
 Among some of the theories other researchers have used to explain diabetes self-
care behaviors and outcomes are the Health Belief Model (HBM), the Theory of Planned 
Behavior (TPB), Social Cognitive Theory (SCT), and Self-Determination Theory (SDT).  
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Research using SDT as a framework to explain diabetes self-care behaviors has yielded 
convincing evidence to support its application as a framework for future studies aimed at 
identifying factors hypothesized to influence patients to engage in self-care activities, 
namely the use of insulin therapy. Existing measures based on the major constructs of 
SDT were used in these studies and determined to be valid and reliable for use in the 
dissertation research. An explanation of the application of these measurements is 
presented in this chapter. 
 Because no research had been conducted to identify predictors of readiness to 
initiate insulin therapy explained within a behavioral framework, a conceptual model was 
developed to illustrate and explain how the study variables of interest were linked to the 
major constructs of SDT. This conceptual model strongly influenced the study’s design. 
Major study variables were operationalized using existing measures including the 
Perceived Competence in Diabetes Scale (PCDS), the Health Care Climate Questionnaire 
(HCCQ), the Treatment Self-Regulation Questionnaire (TSRQ), and the Insulin Therapy 
Appraisal Scale (ITAS). The validity and reliability of these measures are discussed in 
this chapter. 
 In Chapter Four, results of a study using SDT as a framework for identifying 
modifiable predictors of readiness to initiate insulin therapy when oral medications fail to 
control hyperglycemia in patients with T2DM are reported. The specific aim of the study 
was to determine if perceived autonomy-support, perceived diabetes competence, 
motivational orientation, and appraisal of insulin therapy were predictors of readiness to 
initiate insulin therapy in persons with T2DM when oral therapy fails to control 
hyperglycemia.  
11 
 Findings from a descriptive, correlational study of 73 participants with T2DM 
showed that beliefs and attitudes regarding insulin therapy and whether or not they had a 
friend or family member who used insulin were significant predictors of insulin readiness 
(p =.012 and p =.020, respectively). Although perceived diabetes competence, perceived 
autonomy-support in the clinical environment, and motivation orientation were not found 
to be significant predictors of insulin readiness, the findings related to these measures 
have important implications, both in this study and for future research. A discussion 
concerning the usefulness of SDT for studying readiness to initiate insulin therapy, as 
well as recommendations for future research of this phenomenon are addressed in this 
chapter.  
Chapter Summary 
 This chapter provided sufficient evidence to support the scope and importance of 
type 2 diabetes as an important public health problem, now and in the future. Review of 
available literature and justification for the dissertation research were provided. An 
overview of Chapters Two through Four was provided for the reader to describe the 
relationship between the various manuscripts contained in the dissertation.  
 
 
 
 
 
 
Copyright© Pamela Lynn Phares 2011  
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CHAPTER TWO 
Clinical Inertia of Type 2 Diabetes in Primary Care: An Integrative  
Review of the Literature 
OBJECTIVE:  The objective of this paper is to review the available research evidence 
regarding the reluctance of providers to initiate insulin therapy when indicated (clinical 
inertia), in the care of adult patients with T2DM. In addition, future directions for 
research to improve glycemic control for this population of patients are recommended. 
METHOD:  A literature search was conducted using the US National Library of 
Medicine’s MEDLINE database for studies published between 1990 and 2010. Cross-
reference searching using references from reviewed articles, PubMed, and CINAHL was 
also conducted for additional articles until saturation was reached. 
RESULTS:  Fifteen studies were found to meet the criteria for inclusion in this review. 
Interventions to improve glycemic control were employed in five of the studies and 
demonstrated modest but significant improvements in patients’ HbA1c levels. Eight 
studies used prospective designs to evaluate change in HbA1c, and one used a 
retrospective cohort design to analyze previous practice related to patient outcomes. The 
remainder of studies used cross-sectional methods of data collection to evaluate attitudes 
and barriers toward insulin use.  
CONCLUSIONS:  Multiple factors contributing to clinical inertia have been identified. 
Although results of intervention studies to date demonstrate modest but significant 
improvements in HbA1c levels, more research is indicated, as the majority of patients in 
these studies do not achieve recommended glycemic goals. Studies examining individual-
13 
level provider interventions to increase patients’ acceptance of insulin therapy have yet to 
be conducted.  
KEY WORDS: type 2 diabetes; clinical inertia; insulin therapy; diabetes guidelines 
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Introduction 
 Type 2 diabetes mellitus (T2DM) affects both insulin secretion and insulin action. 
The defect in insulin secretion is progressive and is accompanied by concomitant insulin 
resistance, which is believed to begin years before diagnosis (Dewitt & Hirsch, 2003). As 
a consequence of these events, adequate glycemic control in T2DM will eventually 
require exogenous insulin replacement. Up to 60% of diabetic patients will require 
insulin within six to ten years; perhaps sooner if they have experienced long-standing 
disease prior to diagnosis (Barag, 2011).  The UK Prospective Diabetes Study (UKPDS), 
a sentinel study demonstrating improved outcomes with intensive blood glucose control, 
has affirmed that insulin therapy is an integral part of achieving tight glycemic control, 
thus decreasing risk of complications in T2DM (UK Prospective Diabetes [UKPDS] 
Group, 1998).  
 Despite increasing evidence from clinical trials demonstrating markedly improved 
outcomes for diabetes when glycemic control is maintained, a large proportion of patients 
never achieves or maintains glycemic goals (Riddle, 2002). Many experts agree that 
insulin is the most powerful and effective pharmacologic tool available to treat diabetes 
and its potential to lower plasma glucose is limited only by hypoglycemia (Cobble, 
2009). Insulin is grossly underutilized in the U.S. (Riddle, 2002). Insulin therapy in 
T2DM is more often employed only as a last resort when all else has failed, rather than 
used as a highly effective intervention when employed earlier in the disease process. 
Health care providers’ reluctance to prescribe and patients’ reluctance to use insulin are 
often cited as the two major reasons for delay in timely initiation of insulin therapy. 
Delay in initiating insulin in patients who are unable to reach optimal glycemic control 
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with oral diabetic agents increases their risks of microvascular and macrovascular 
complications (Cobble, 2009).   
  Estimated prevalence of diabetes, as of 2007, is 7.8% of the U.S. population, or 
23.6 million Americans (American Diabetes Association [ADA], 2009). Approximately 
90-95% of these cases are type 2 diabetes. Diabetes is a common medical problem and as 
such has been widely researched in terms of best practices related to its treatment. Well-
researched practice guidelines exist for managing diabetes; yet a wide gap exists between 
recommended medical practices and the care patients actually receive in the clinical 
setting. The role of primary care providers in managing T2DM continues to expand and 
they are more likely than specialists to initiate and manage insulin therapy in these 
patients (Barag, 2011). Many primary care providers rate effective treatment of diabetes 
as one of the most difficult and time consuming of patient health problems dealt with in 
practice (Brunton, 2009). In fact, the cross-national Diabetes Attitudes, Wishes, and 
Needs (DAWN) study found that a large number of U.S. primary care physicians were 
inclined to delay initiation of insulin in their diabetic patients (Peyrot et al., 2005). 
Furthermore, evidence suggests that U.S. primary care providers typically do not initiate 
insulin therapy until a patient’s glycosylated hemoglobin (HbA1c) level reaches ≥ 9% 
which corresponds to an average serum glucose of 243 mg/dl (Brown, Nichols & Perry, 
2004). 
 Effective management of hyperglycemia through intensification of therapy has 
been well demonstrated by researchers, but poorly implemented in practice (Peyrot et al., 
2005; UKPDS, 1998). A major reason for poor glycemic management has been identified 
as the phenomenon of clinical inertia, which is defined as the failure of healthcare 
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providers to initiate or intensify diabetes therapy when indicated in the course of the 
disease (Perlin & Pogach, 2006). The purpose of this paper is to review the available 
research evidence regarding the reluctance of providers to initiate insulin therapy when 
indicated in adult patients with T2DM. Specific aims of this literature review are: (1) to 
identify factors that have been shown to contribute to clinical inertia of primary care 
providers starting insulin therapy in T2DM, (2) to identify strategies that have 
successfully decreased the clinical inertia of primary care providers initiating insulin 
therapy in the care of patients with type 2 diabetes, and (3) to identify individual-level 
strategies employed by primary care providers with type 2 diabetic patients to overcome 
clinical inertia and facilitate patient use of insulin therapy earlier in the disease course. 
While acknowledging the importance of patient factors contributing to the avoidance or 
delay of insulin therapy initiation, the focus of this review is on the provider aspect of 
this clinical issue. 
 Specific aims of this review were guided by the following questions: (1) What 
factors are related to the clinical inertia of healthcare providers avoiding or delaying 
insulin therapy in patients with type 2 diabetes? (2) What strategies have been successful 
in diminishing clinical inertia of healthcare providers when the patient’s clinical 
condition warrants insulin therapy? (3) What individual-level interventions have been 
used by healthcare providers to increase patient acceptance of insulin therapy?  
Method 
 The literature search was conducted using the US National Library of Medicine’s 
MEDLINE database. The search included articles published in English only, beginning in 
1990 and ending in 2011. Cross-reference searching using references from reviewed 
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articles, PubMed, and CINAHL was also conducted to identify additional articles. The 
search was discontinued when saturation was evident from repetition of articles 
appearing in the various searches. Key words and phrases used in the search included: 
diabetes treatment, type 2 diabetes, barriers to treatment, facilitators of insulin 
prescribing, insulin initiation, clinical inertia, insulin avoidance, hypoglycemia, beliefs, 
attitudes, perceptions, transition to insulin, glycemic control, resistance to insulin therapy, 
psychological resistance, physician, nurse, and misconceptions regarding insulin. No 
limitations were placed on the type of study design or size of the sample. Articles 
pertaining specifically to T2DM were targeted. A total of 152 citations were retrieved 
from the initial MEDLINE search and cross-referenced searches. After reviewing 
abstracts, 43 articles were analyzed for content related to clinical inertia. Studies were 
included if they were: (1) primary sources and (2) they specifically addressed 
investigations pertaining to clinical inertia in the treatment of adult patients with T2DM. 
Fifteen studies were found to meet the criteria for inclusion in this review and are 
described in Table 2.1.  
Results 
Factors Contributing to Clinical Inertia 
 Clinical inertia has been defined as the failure of clinicians to appropriately 
initiate or intensify diabetes therapy when indicated in the course of the disease (Perlin & 
Pogach, 2006). Intensification can be defined as an increase in the dosage, number, or 
type of antiglycemic agents necessary to maintain near-normal blood glucose levels in 
diabetic patients (Cobble, 2004). Diabetes therapy is considered to be failing when 
glycosylated hemoglobin (HbA1c) exceeds 7% according to ADA standards (2011).  
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 Since the majority of patients with T2DM are managed in primary care settings, 
much of the concern with clinical inertia is centered on whether timely and appropriate 
clinical decisions are being made regarding intensification of diabetes treatment using 
insulin (Cobble, 2004; Pearson & Powers, 2006). The clinical endpoint most often used 
to gauge efficacy of diabetes treatment established by the ADA is HbA1c, as it is 
considered a reliable measure of a diabetic’s long-term glycemic control (ADA, 2009; 
Dewitt & Hirsch, 2003). Most of the studies examining clinical inertia in the primary care 
setting also used HbA1c as a measure of the effectiveness of diabetes care and 
interventions.  
 Competing demands in primary care 
 Ziemer and colleagues (2005) conducted a large prospective observational study 
to compare management of diabetic patients in a primary care clinic versus a diabetes 
specialty clinic. Findings from the study showed that when serum glucose levels were 
high, therapy of diabetic patients in the primary care clinic was much less likely to be 
advanced or intensified compared to diabetics in the specialty diabetes clinic (32% vs. 
65%, p < .0001). In this same study, intensification rates for insulin therapy in patients 
currently using insulin were strikingly lower in the primary care clinic than the diabetes 
clinic (28% vs. 75%, p < .02). Researchers conducting the study concluded that the low 
rates of therapy intensification for patients in the primary care clinic were a function of 
their comorbid health problems and other primary care patient concerns that are 
necessarily addressed in that environment, but are not typically addressed in a specialty 
clinic. Similarly, a study by Parchman and colleagues (2007) found that for each 
additional patient concern in a primary care office, there was a 49% reduction in the 
19 
likelihood of a medication change, and once the number of patient concerns exceeded 
four, none of the observed patient encounters had a change in medication regardless of 
HbA1c value. However, researchers found that when a medication change occurred 
during a patient encounter, not only were fewer patient concerns discussed at the visit (p 
= .04), but patients also had a higher HbA1c value than in those encounters not involving 
medication changes (p = .001) 
 Lack of training and failure to follow published guidelines 
 Many of the studies reviewed examining clinical inertia were conducted in 
response to the Diabetes Quality Improvement Project (DQIP) initiated in 2001 to 
establish a set of comprehensive national quality measures for diabetes care (Fleming et 
al., 2001). Despite the publication and dissemination of expert guidelines for managing 
T2DM that resulted from the DQIP initiative, implementation of those guidelines and 
providers’ knowledge of them remain quite variable (Perlin & Pogach, 2006). In an 
observational study involving 30 academic medical centers, researchers failed to identify 
specific factors explaining clinical inertia (Grant, Buse & Meigs, 2005). They found that 
only 34% of diabetic patients were maintained at HbA1c goal (< 7.0%). Given that most 
academic medical centers generally promote cutting-edge health care initiatives, serve as 
training grounds for new healthcare providers, and are centers of substantial clinical 
research and scientific inquiry, this finding is particularly concerning.  
 A descriptive epidemiologic study of insulin-dependent diabetic patients managed 
by resident physicians at a major teaching hospital was conducted by Giangola et al. 
(2008). Only 5.7% of the 105 diabetic patients who participated in the study exhibited 
adequate glucose control. The top three barriers to glycemic control identified by 
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researchers were: reluctance of the physician to increase insulin dosage, reluctance to 
follow the advice of the diabetic team nurses, and general lack of knowledge about 
insulin therapy. Although lack of knowledge and need for additional training were not 
identified by internal medicine residents in an academic medical center (n = 145) as 
barriers to their implementation of national diabetes guidelines and getting patients’ 
HbA1c levels to goal, Bernard, Anderson, Cook and Phillips (1999) found that fewer than 
half of the medical residents being studied selected an appropriate HbA1c goal for their 
patients. Findings also revealed that 51% of those patients who had been prescribed oral 
antiglycemic agents and 47% of those receiving insulin had recorded HbA1c levels in 
excess of 8%. Physicians’ self-rated performance and knowledge regarding appropriate 
use of insulin in T2DM and correct implementation of national diabetic treatment 
guidelines were quite different from the actual practices observed by researchers 
conducting the study.  
 Physician attitudes and patient noncompliance 
 Attitudes and misconceptions of primary care physicians have been identified in 
other studies as barriers to glycemic control in diabetic patients. Larme and Pugh (1998) 
surveyed 31 primary care providers treating T2DM patients who rated diabetes as harder 
to treat than other chronic diseases such as hypertension, hyperlipidemia, angina, and 
arthritis. Major attitudinal themes that emerged as barriers to glycemic control were 
complexity of treatment, time and expense, frustration over poor glycemic control, 
diagnosis and treatment protocols perceived to be unclear and eventual decline of the 
patient despite prescribed therapy.  
21 
 Similar to the study by Larme and Pugh, Drass et al. (1998) surveyed 370 primary 
care providers who managed diabetic care of their patients and also found time and 
expense, complexity of diabetes care, and perceived lack of clear care guidelines to be 
barriers to effective medical management of patients with T2DM. Additionally, providers 
in this study rated patient nonadherence to treatment as the most problematic barrier to 
glycemic control. A subsequent prospective cohort study of 2,065 patients with T2DM by 
Grant et al. (2007) highlighted the important relationship linking patient behavior 
(adherence) and physician action (intensifying diabetes therapy). Researchers in this 
study found that patients in the highest baseline medication adherence quartile had 53% 
greater odds of having their therapy intensified relative to rising HbA1c when compared 
to those patients in the lowest quartile (p < .0001). The authors point out however, that 
even among the most adherent patients with rising HbA1c, intensification of their diabetes 
regimen was delayed for almost two years in most cases. This study confirmed suspicions 
of researchers that poor adherence, or even perceived poor adherence, dooms some 
patients to inadequate management of their diabetes. 
 A descriptive study by Bernard et al. (1999) examined both the self-described and 
recorded behaviors of internal medicine (IM) residents (n = 161) caring for T2DM 
patients (n = 140) in an effort to target areas for improvement in the internal medicine 
residents’ practice patterns regarding diabetes care. Results indicated that less than half 
(49%) of residents selected a targeted HbA1c range of 6.6% to 7.5% as attainable, but 
more than half of patients using either oral medications or insulin in the study had HbA1c 
values > 8%. In addition, incremental years of additional practice had no effect on self-
described versus recorded clinical performance of the resident trainees. Overall, IM 
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residents did not perceive themselves to need additional training in diabetic care when 
asked, as evidenced by average neutral ratings on a 5-point Likert scale (µ = 3.1 ± 0.4) 
for all four questions that assessed perceived need for additional training. They were also 
neutral about their regard for patient autonomy in the clinical care setting (µ = 3.3 ± 0.6). 
Similar to previous research findings, residents in this study rated patient nonadherence 
(71%) and time constraints (49%) as often or always a barrier to effective care.   
 Findings from the large, cross-national Diabetes Attitudes, Wishes, and Needs 
(DAWN) study  revealed U.S. physicians ranked lowest among physicians in all but two 
nations, Japan and India, in their willingness to initiate insulin in their patients with 
T2DM (Peyrot, Rubin, Lauritzen, Skovlund, Snoek, et al., 2005) . Both nurses and 
physicians who took part in this study identified insufficient training and lack of 
resources in the primary care setting as significant barriers. Perhaps the most shocking 
finding was that barely more than half of U.S. nurses (n = 1,109) and physicians (n = 
2,681) interviewed in this study believed in the efficacy of insulin for T2DM. Diabetes 
specialists and clinical opinion leaders in this study were far more likely to initiate insulin 
therapy to control hyperglycemia, a finding consistent with that from the study by Perlin 
and Pogach (2006). Both non-belief in the efficacy of a treatment and lack of knowledge 
in the correct or optimal use of that therapy may strongly impact one’s propensity to 
prescribe it, and may represent a substantial barrier to implementation of evidence-based 
guidelines in the management of diabetic patients in the primary care setting. 
 Misconceptions of barriers to insulin therapy  
 Misconceptions held by healthcare providers which they attribute to a patient’s 
reluctance to use insulin or fear of insulin therapy in general have been shown to 
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contribute to the clinical inertia of health care providers to prescribe insulin to patients.  
Nakar, Titzhaki, Rosenberg, and Vinker (2007) administered an open-ended 
questionnaire to 157 family physicians caring for type 2 diabetic patients in order to 
explore reasons for their reluctance to initiate insulin treatment. The most frequent 
explanations given by physicians were: the patient would not comply with treatment 
(92.3%), fear of hypoglycemia in a specific patient (79.7%), patients would not be able to 
cope with pain involved in blood testing (53.9%) and injecting (48.4%), and the patients 
being too old (47.4%). These barriers were in sharp contrast to the patients’ most 
frequently perceived barriers to insulin therapy which were: diabetes is not a serious 
illness (46.7%) and fear of addiction to insulin (39%). Pain and hypoglycemia were very 
infrequently cited patient barriers (5.4% and 12%, respectively).  
Strategies to Decrease Clinical Inertia and Improve HbA1c 
 Few studies focusing on overcoming clinical inertia of primary care providers 
managing T2DM have been conducted. Selected studies for this review of the literature 
included those that implemented stepped-approach algorithms into clinical practice 
(Aubert et al., 1998; Benjamin, Schneider, & Hinchey, 1999; de Sonnaville et al., 1997) 
and those that evaluated the feasibility and outcomes of newly-formed collaborative care 
models between primary care providers and endocrinologists (Graber, Elasy, Quinn, 
Wolff & Brown, 2002; Phillips et al., 2005).  
 Integrating evidence into practice: stepped-approach algorithms 
 Structured stepped-approach algorithms became more widely recommended by 
experts and opinion leaders following the UKPDS study (1998) in which researchers 
demonstrated markedly improved glycemic control through treatment intensification in 
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management of T2DM. Diffusion of these guidelines and recommendations into clinical 
practice has not been effectively accomplished (DeWitt & Hirsch, 2003; Hsu, 2009; 
Parchman et al., 2007). A study by de Sonnaville et al. (1998) tested the implementation 
of a fairly aggressive stepped approach to diabetes treatment intensification with 
physicians in a primary care setting. The prospective, experimental study included an 
intervention group of type 2 diabetic patients not treated with insulin (n = 350) and a 
control group (n = 68) of type 2 diabetic patients already using insulin. The two groups 
were followed over a two-year period. A step-up regimen of medication intensification 
was instituted within the study group with change in therapy triggered by a patient’s 
HbA1c level exceeding 7.0%. The percentage of patients that were prescribed insulin 
increased from 3.56% at baseline to 20% in one year and almost 30% in two years. The 
majority of patients in the study group (54.3%) achieved HbA1c levels < 7.0%, while the 
control group did not (44.1%). These differences were significant (p = 0.013). Despite 
aggressive intensification of therapy for their diabetes, self-reported well-being of the 
treatment group participants remained unchanged and only four episodes of 
hypoglycemia occurred over the two-year period.  
 Aubert and colleagues (1998) studied a stepped-approach protocol of medication 
intensification using a randomized controlled trial design. Interventions with patients 
were implemented via a case management model using a certified diabetes nurse educator 
under the direction of a family physician and endocrinologist. The intervention group (n 
= 138) received extensive teaching from the nurse case manager with reinforcement of 
behavioral changes; those taking insulin were contacted by phone twice per week by the 
nurse specialist. The control group received usual care, education, and follow-up. Change 
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in HbA1c value was the comparative outcome measure. The intervention group had a 
decrease in HbA1c of 1.7% (p =.001), while the control group demonstrated only a 0.6% 
decrease in HbA1c. In addition, patients in the intervention group were more than twice as 
likely to report greater well being than patients in the control group (p = .02). This 
particular finding was encouraging because decline in well-being has been cited by some 
experts as a barrier to insulin therapy.   
 A third study by Benjamin, Schneider, and Hinchey (1999) also employed a 
stepped-approach algorithm for medication regimen intensification. The study’s design 
was a prospective controlled trial that used firm systems, which are separate but parallel, 
clinical group practices that share no patients and no providers. Firm systems are ideally 
suited to capture the impact of a disease management program. Researchers used these 
parallel practices as study and control groups for comparison of glycemic outcomes in 
diabetic patients. The intervention group (n = 67) utilized a piloted practice guideline that 
intensified a patient’s anti-glycemic therapy based on HbA1c levels exceeding the trigger 
point of 7.5%. The control group (n = 77) received usual care. In addition, guideline 
adherence by physicians participating in the study was monitored by individual chart 
audit. There was a significant decrease in HbA1c for the intervention group at both nine 
and 15 months (p = 0.001 and 0.006, respectively). Not surprisingly, individual physician 
compliance with the intervention protocol was found to be variable (45% to 91%) on 
serial chart audits. It should be noted that although mean HbA1c improvement from 
baseline in the intervention group was significant, it was still well above the ADA goal of 
< 7.0%. 
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 All of the studies reviewed used experimental prospective designs with HbA1c as 
the clinical evaluation endpoint for efficacy of treatment. Although improvements in 
glycemic control were realized and were statistically significant in all studies, they were 
modest improvements at best. A large proportion of patients in all studies remained well 
above the ideal HbA1c goal set by the ADA, thus placing them at risk for serious disease 
sequelae (ADA, 2009).  
 Testing collaborative care-models 
 While evidence-based treatment algorithms and guidelines are available to assist 
primary care physicians in the optimal treatment of T2DM and implementation of these 
has been demonstrated to improve glycemic control in diabetic patients, many primary 
care providers continue to rely on referrals to endocrinologists when patients require 
insulin therapy to manage their hyperglycemia (Peyrot et al., 2005). This is due in large 
part to primary care physicians’ lack of training or knowledge, scheduling pressures, and 
inadequate resources for transitioning patients to insulin therapy (Larme & Pugh, 1998). 
The following two studies evaluated collaborative models of care between primary care 
providers and endocrinologists which have yielded some promising findings.  
 Phillips and colleagues (2005) conducted a controlled trial over a three-year 
period to examine the effects of patient-specific treatment recommendation reminders 
and short, retrospective bi-weekly face-to-face feedback sessions from endocrinologists 
on the clinical performance of resident physicians caring for type 2 diabetics in the study. 
No consultation services were offered by the endocrinologists regarding treatment 
recommendations. A structured treatment intensification algorithm consistent with ADA 
guidelines and recommendations was developed for residents to implement in the clinic 
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setting during the trial. The study took place in a large, urban academic medical center in 
Atlanta and involved 4,038 patients who were seen in continuity clinics for their T2DM 
by 345 medical residents. Residents were randomized to either the control or one of three 
intervention groups. The three intervention groups were: reminder system only, feedback 
on performance only, or a combination of both. The control group received usual care. 
Individual patient HbA1c values were used as the clinical endpoint for evaluation of 
residents’ clinical performance in managing patients’ diabetes care. The combined 
reminder system with feedback from endocrinologists was found to produce a significant 
reduction of HbA1c (0.6% reduction, p < 0.02) compared with the control group and the 
two other intervention groups.  
 A somewhat different collaborative model was tested in a study by Graber and 
colleagues (2002). This study evaluated the effect of allocating endocrinology-directed 
resources for intensive educational intervention with type 1 and 2 diabetic patients 
referred by primary care physicians. The endocrinology-directed resources included a 
team of certified diabetic nurse educators and dieticians working with the department of 
endocrinology at an academic medical center in Nashville, Tennessee. The intervention 
included 12-weeks of multifaceted, intensive educational and behavioral counseling for 
diabetic patients with the dieticians and nurses under the direction of endocrinologists. A 
key feature of the intervention was frequent communication of patient progress and 
medication changes between the nurses and the primary care physicians in an effort to 
increase the primary physician’s role and responsibility in management of their own 
patients. Efficacy of the intervention was determined by change in mean HbA1c levels 
from baseline with patients serving as their own controls. A total of 350 patients, 250 of 
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which were type 2 diabetics, completed the program. Mean HbA1c levels decreased by 
1.7% (p =.000). This finding was consistent with that of Phillips et al. (2005). Both 
studies demonstrated how accessibility of specialty diabetic services to primary care 
providers and shared management of these patients can result in improved glycemic 
control for patients.  
 Use of technology to improve patient outcomes  
 Grant and colleagues (2006) identified two key barriers to optimal T2DM care 
that were considered amenable to technology-based intervention. These were (1) lack of 
patient engagement in their therapeutic care plans and (2) lack of medication 
intensification by physicians during clinical encounters with patients. The research group 
developed a comprehensive patient web portal that allows patients to interact directly 
with their electronic health record (EHR) into which their current clinical data is 
imported and integrated into an educational format. The educational format provides 
patient-tailored medical decision support and enables patients to design their individual 
“Diabetes Care Plan” which is visible to the patient’s clinician. The setting in which this 
T2DM web portal was implemented was a large urban healthcare network in Boston, 
Massachusetts that includes multiple hospitals, physician practices, and over one million 
total patients. Fourteen primary care practices within the targeted health network are 
currently participating in an ongoing randomized controlled trial evaluating this 
intervention. Results are expected soon. 
Discussion and Conclusion 
 Researchers have demonstrated that clinical inertia in primary care of type 2 
diabetes is influenced by a variety of factors. Although relatively few studies of these 
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factors have been conducted, findings from these studies have been important. Perhaps 
the most important of these is the level of complexity required for treating type 2 
diabetics, in addition to various other patient comorbidities, which leaves insufficient 
time for providers to appropriately address persistent hyperglycemia in a primary care 
setting. Since the majority of type 2 diabetic patients currently receive care from primary 
care providers, complexity may continue to hinder glycemic control unless structural 
changes occur in primary care settings. Concomitantly, lack of training, limited 
knowledge, and insufficient diabetes care resources add to perceived complexity, 
frustration, and resultant clinical inertia. Some researchers suggest that a paradigm shift 
from acute care focus to a chronic-illness care model needs to occur in primary care, so 
that needs of diabetes can be adequately addressed in that environment (Ziemer et al., 
2005). This point is especially pertinent given the large proportion of patients who 
receive diabetes care and treatment from a primary care provider. 
 Patient adherence to medication regimens is problematic in all chronic illnesses 
and diabetes is no exception. However, it is incumbent upon health care providers to offer 
insulin therapy to diabetic patients who are not at HbA1C goal on oral therapy. The 
evidence suggests that poor medication adherence by patients, whether real or imagined, 
adversely affects a physician’s tendency to intensify a patient’s diabetic therapy, 
particularly so with initiation of insulin therapy. Research findings also suggest that 
physician attitudes toward insulin and misconceptions about perceived patient barriers to 
insulin therapy often deters them from considering insulin as an option for patients, 
despite its proven therapeutic efficacy as a powerful antiglycemic agent in T2DM (Grant 
et al., 2007).  
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 Research findings from the studies reviewed suggest that disregard for established 
treatment guidelines, lack of belief in insulin efficacy, and lack of knowledge or 
insufficient training regarding insulin therapy are problem areas that are amenable to 
educational interventions, system changes, and open collaboration with experts in 
diabetes care (Aubert et al., 1998; Benjamin et al., 1999; de Sonneville et al., 1997; 
Fleming et al., 2001; Grant et al., 2005; Nakar et al., 2007; Peyrot et al., 2005; Phillips et 
al., 2005). Although some of the intervention studies were small, their prospective 
experimental designs allowed for comparisons between usual care groups versus 
intervention groups, the latter of which showed improved outcomes. Whether these 
changes are sustainable over the long-term will still need to be evaluated through 
research. 
 Some evidence suggests that the content and extent of information shared 
between provider and patient is significantly associated with overall self-management 
success in diabetic patients (Graber et al., 2002). The manner in which the need for 
medication intensification, particularly insulin therapy, is communicated by the provider 
can strongly influence its acceptance by the patient (Barag, 2011). Further evidence 
indicates that when patients perceive negative attitudes from the provider towards insulin 
therapy, their willingness to consider it diminishes (Heisler, Bouknight, Hayward, Smith 
& Kerr, 2002). Patients require rationale for treatment, adequate and accessible 
information, and support from primary care providers to consider and embrace insulin 
therapy. Future research should focus not only on changing the paradigm of diabetes 
treatment in a primary care setting, but also on provider-initiated strategies to support 
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patient autonomy and encourage patient acceptance of timely initiation of insulin therapy 
to accomplish effective glycemic control in T2DM. 
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Table 1.1 Summary of Studies on Clinical Inertia 
      Mean Age Mean 
Author   n      (years)  A1C  Study Type    Outcomes 
 
de Sonnaville et al. T* = 350   65.3  7.4%  Prospective cohort T  Group: A1C decreased to 7.0%  
1997   C† = 68   64.6  7.4%  controlled trial  C  Group: A1C increased to 7.6% 
 
Drass et al.14  370   n/a  n/a  Survey:   33.3% response rate; primary care MDs w/  
1998          questionnaire &  24.5 yrs avg. experience; 92% felt A1C  
          Likert scale  goal achievement was most important aspect 
             of diabetic care (100%); Considered A1C  
             goal of < 8.0% adequate (92%); Non- 
             adherence to current regimen most common 
             barrier to care  
 
Larme & Pugh  31   40.8-45.4 n/a  Survey: Likert scale Diabetes rated as harder/more complex 
1998          and interviews  to treat than hypertension, angina,   
             arthritis, hyperlipidemia; Major explanatory 
             themes that emerged: inability to affect  
             outcomes of disease despite intervention,  
             complexity of care, lack of societal &   
             healthcare system support to control  
             diabetes 
 
Aubert et al.  T = 71   53  8.8%  RCT   T Group: A1C decreased by 1.7% which 
1998   C = 67   54  8.4%     which was significant comp. to control 
             C Group: A1C decreased by 0.6% 
 
 
Bernard et al.  145   28  n/a  Survey & chart review 49% of residents selected correct A1C goal 
1999             but chart review of their patients showed 
             actual A1C in 51% of patients on oral meds 
             and 47% on insulin were > 8.0% 
 
*T = Treatment Group; †C = Control Group 
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Table 1.1 Summary of Studies on Clinical Inertia (continued) 
      Mean Age Mean 
Author   n   (years)  A1C  Study Type    Outcomes 
 
Benjamin et al.  T = 67   54.3  9.3%  Prospective,  T  Group: A1C decreased to 8.42% at 9 mo.  
1999   C = 77   52.0  9.21%  controlled trial   and was 8.68% at 15 mo. 
             C  Group: A1C increased to 9.41% at 9 mo. 
              and decreased to 9.15% at 15 mo. 
 
Graber et al.  350   51  9.4  Prospective,  1.7% decrease in A1C which was  
2002          intervention  significant. 
          (no control) 
 
Peyrot et al.  (RN) 1,109  46  n/a  Survey & structured  U.S. RNs and MDs: significantly more  
2005   (MD) 2,681  41    interview  likely to delay insulin until critical; more  
             likely to use insulin if pt. adherent to 
             current therapy; less likely to see insulin as 
             efficacious 
 
Ziemer et al.  (MC) 438  63  8.6%  Prospective  No difference in demographic variables 
2005   (DC) 2157  59  7.7%  observational  between pts in medical clinic (MC) vs.  
             diabetic clinic (DC); significant difference 
             in A1C between clinics; significantly less  
             use of insulin in MC than DC; MC pts  
             significantly less likely to have medication 
             regimen intensified 
Grant et al.  1,765        
2005     (MC) 1,175  57.9  8.1%  Retrospective  Compared care of medical center (MC) and 
     (DC) 590  54  7.9%  cohort   diabetes center (DC) pts in 30 academic  
             centers around U.S. Results: only 34% of pts 
             w/A1C < 7.0%; only 40.4% of pts had  
             medication intensified if A1C > 7.0%; DC  
             pts significantly more likely to have meds  
             intensified 
 
*T = Treatment; †C = Control 
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Table 1.1 Summary of Studies on Clinical Inertia (continued) 
      Mean Age Mean 
Author   n   (years)  A1C  Study Type    Outcomes 
 
Phillips et al.  Total  = 4138  59  8.1%  Controlled trial  Followed pt. care of 345 medical residents:  
2005     T1 = 1,043 (REM)        Significant decrease in A1C of pts in T3 
     T2 = 1,049 (FB)         which was FB (feedback) + REM   
     T3 = 1,063 (FB + REM)        (reminders); NS differences in demographic  
     C = 983         variables; T1 & T2 not significant 
 
Nakar et al.  Patients:       Case-control  Illness not serious: TG (46.7%) v. CG (7%); 
2007     T = 92 (no insulin) 62.6  n/a  descriptive  fear of insulin addiction: TG (39%) v. CG  
     C = 101 (insulin) 60.3    interviews  (20.8%); hypoglycemia TG (12%) v. CG  
   Physicians:         (4%)—all significant pt. barriers   
     157   45       Physician barriers: Pt. noncompliance  
             (92.3%), hypoglycemia (79.9%), pain  
             w/blood tests (53.9%) and pain of injection  
             (47.4%) 
 
Parchman et al.  177   59  >7.0%  to  Cross-sectional;  Encounters w/change in medication were 
2007        >9.0%  direct    longer, involved fewer pt concerns, had 
          observation  higher most recent A1C values; once the 
             # of pt concerns exceeded 4, no changes in 
             medications were made; those w/high A1C  
             and no medication change were seen avg. of  
             8.6 days earlier on return visit 
 
Grant et al.  2,065    55.4  9.4%  Prospective cohort 33.3% of cohort had medication intensified  
2007          correlational  over 12 mo. period; Pts in highest A1C  
             quartile significantly more likely than lowest 
             quartile to have medication intensified; Pts  
             w/high adherence to current regimen  
             significantly more likely to have medication 
             intensified 
 
*T = Treatment; †C = Control 
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Table 1.1 Summary of Studies on Clinical Inertia (continued) 
      Mean Age Mean 
Author   n   (years)  A1C  Study Type    Outcomes 
 
Giangola et al.  105   68  6.87%  Observational  Barriers to glucose control identified by  
2008             diabetes care team in hospital setting; only  
             5.7% of pts had adequate glycemic control;  
             nurses coded 398 barriers to the 202 patient 
             interventions during hospitalization; major  
             barriers identified: therapeutic reluctance,  
             inappropriate prescribing & use, knowledge  
             deficit, diabetes team not consulted in timely 
             manner; outpatient diabetes meds not  
             restarted after surgery 
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CHAPTER THREE 
Self-Determination Theory as a Framework to Investigate Predictors of 
Readiness to Initiate Insulin Therapy in Type 2 Diabetes 
Introduction 
 Diabetes is a multidimensional, complex chronic disease which is often not 
diagnosed until four to seven years after the onset of glycemic changes that are capable of 
causing damaging microvascular complications (Harris, Klein, Welborn & Knuiman, 
1992). It is the insidious decline of pancreatic insulin secretion and the concomitant 
increase in plasma glucose levels that characterize the natural progression of type 2 
diabetes mellitus (T2DM); making the disease largely asymptomatic in most individuals 
initially, until symptoms of macrovascular and microvascular organ damage begin to 
surface from continued uncontrolled hyperglycemia (Brietzke, 2007; Gerich, 2003). 
Meticulous and consistent control of serum glucose has been identified by diabetes 
researchers as the single most important intervention to prevent or delay diabetic 
complications (Blonde, 2004; Brietzke, 2007; Nakar, Yitzhaki, Rosenberg & Schlomo, 
2007; UK Prospective Diabetes Study [UKPDS] Group, 1998).   
 Unfortunately, a large proportion of patients with T2DM does not achieve or 
maintain effective control of hyperglycemia for a variety of reasons. Prolonged poor 
control of serum glucose levels results in significant morbidity and poor quality of life 
(Alberti, 2002; Anderson, Freeland, Clouse & Lustman, 2001; UKPDS, 1998). Achieving 
optimal glycemic control requires patients with T2DM to fully engage in multiple life-
long behavioral changes, focused primarily on lifestyle modifications and complex, daily 
self-management skills (monitoring symptoms, testing blood glucose levels, taking 
medications appropriately) from the outset of diagnosis. Due to the complexity of T2DM 
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management, as well as the asymptomatic nature of early disease, many patients, 
understandably, have substantial difficulty following the prescribed treatment regimen. 
This in turn exacerbates the severity of the illness and accelerates the need for treatment 
intensification, which often involves insulin therapy (IT), to avoid disease complications 
(Norris, Engelau & Narayan, 2001; Steed, Cooke & Newman, 2003). Patients are as 
reluctant to use insulin as health care providers are to prescribe it for T2DM (Peyrot et 
al., 2005). The purpose of this paper is to identify and apply an appropriate theoretical 
framework on which to base an investigation of predictors of readiness for persons with 
type 2 diabetes who require transition to IT when oral therapy fails to control 
hyperglycemia. 
 Traditional management approaches in T2DM often rely too long on conservative 
therapies, even in the face of continued escalation in patients’ glycosylated hemoglobin 
(HbA1c) levels, instead of intensifying therapies earlier (Perlin & Pogach, 2006). In 
addition, health care providers tend to wait until multiple oral therapy combinations fail 
to control hyperglycemia before initiating insulin therapy despite expert 
recommendations to the contrary (Riddle, Rosenstock, Gerich & Insulin Glargine 4002 
Study Investigators, 2003; Brietzke, 2007; Nakar et al., 2007). Many experts agree that 
insulin is the most powerful and effective pharmacologic tool available to treat 
hyperglycemia and it will eventually be necessary to effectively control blood glucose in 
a substantial number of patients with T2DM as beta cell failure progresses as a natural 
course of the disease (Cobble, 2009; Riddle, 2002).  
 Clinical inertia on the part of health care providers to initiate insulin therapy and 
reluctance or resistance on the part of patients to embrace insulin therapy as part of their 
treatment regimen are common reasons, well-supported in the literature, that contribute to 
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the underuse of insulin in the management of T2DM (Grant et al., 2007; Peyrot et al., 
2005). Perhaps one of the most problematic contributors to provider clinical inertia 
identified during investigations of this phenomenon are the negative attitudes held by 
diabetes practitioners regarding their perceptions of patients’ nonadherence to self-care 
practices. A study by Drass and colleagues (1998) surveyed 370 primary care providers 
who managed diabetic care found that time and expense, complexity of diabetes care, and 
lack of clear care guidelines to be barriers to effective care. In addition, providers rated 
patients’ nonadherence to treatment as the most frustrating and problematic barrier to 
glycemic control. A subsequent prospective cohort study of 2,065 patients with type 2 
diabetes by Grant, Buse and Miegs (2005) highlights the important relationship linking 
patient behavior (adherence) and physician action (intensifying diabetes therapy). 
Researchers in this study found that patients in the highest baseline medication adherence 
quartile had 64% greater odds of having their therapy intensified (including initiation of 
insulin therapy) relative to rising HbA1c than compared to those patients in the lowest 
quartile. Perceived poor adherence patterns may therefore doom some patients to 
inadequate management of their hyperglycemia due to their provider’s negative attitudes 
and frustration toward misunderstood behaviors related to self-care regulation in these 
patients.  
Compliance, Adherence, and Self Care in Type 2 Diabetes 
 The concept of treatment compliance, or adherence, emerged from a health care 
paradigm representing a time when the majority of illnesses and diseases were acute in 
nature (Anderson & Funnell, 2000). This paradigm promulgates the notion that health 
care providers must assume the primary responsibility for ensuring that their patients 
engage in the prescribed treatments. In addition, this view presupposes that the health 
 39 
 
care provider controls a patient’s self-management decisions and engagement in optimal 
diabetes self-care activities.  
 Anderson and Funnell (2005) argue that under this acute-care paradigm, patients 
who fail to perform to a provider’s expectations are labeled as noncompliant or 
nonadherent, which eventually leads to the development of dysfunctional and corrosive 
relationships between providers and patients to the disservice of both parties. They 
contend that a more effective and appropriate paradigm for diabetes care embraces a 
model that positions the patient at the center and in control of managing his or her 
disease, while the health care provider is positioned in the supportive roles of 
collaborator, facilitator, and educator. 
 Leading experts in diabetes care believe that patients with diabetes are fully 
responsible for the course and outcomes of their illness, because the most important 
choices affecting the health and well-being of the person with diabetes are made by those 
with the disease, not their health care provider or diabetes educator (American Diabetes 
Association [ADA], 2003; Anderson & Funnell, 2000; Funnell & Anderson, 2004; Steed 
et al., 2003; Weinger, 2007). Eliminating the concepts of compliance and adherence from 
the new paradigm of diabetes care involves incorporating a truly collaborative model 
between health care providers and their patients that maximizes patient autonomy. This 
will mean abandoning assumptions of power, control, judgment, and blame on the part of 
the health care provider, while instead empowering patients to choose and experiment 
with self-care interventions in deciding what works best for them in managing their 
diabetes in everyday life (Anderson et al., 2009; Anderson & Funnell, 2000; Barlow, 
Wright, Sheasby, Turner & Haisnworth, 2002).  
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 In order to understand autonomous, agent-initiated self-care behavior in this new 
paradigm of diabetes care, an appropriate theoretical framework on which to base 
behavioral management strategies and treatment interventions for T2DM will need to be 
identified. A review of the literature was performed to investigate behavioral theories and 
frameworks that have been proposed in order to explain or understand diabetic patients’ 
engagement in self-care behaviors, particularly with regard to insulin therapy.   
Understanding Self-Care Behaviors in Type 2 Diabetes:  
A Review of the Literature 
 A variety of factors account for individual variations in self-care behaviors of 
people with chronic diseases. Early studies of health-related behaviors identified certain 
demographic variables associated with performing healthy behaviors including age, 
gender, race, socioeconomic status (SES), social support, and education (Conner & 
Norman, 2005; Harvey & Lawson, 2008). Consistently, it has been demonstrated in 
studies that those individuals who are white, wealthier, have more education, fewer 
stressors, and greater social support are significantly more likely to engage in healthy 
behaviors than those who are older, poorer, less educated, and non-white. While it is 
important to identify these individual behavioral risk factors, they are largely 
unchangeable and therefore not amenable to modification through clinical or behavioral 
interventions.  
 Various health belief theories emerged as behavioral scientists began to realize 
the importance of subjective psychological processes that affected health-promoting 
behaviors as well as illness-related behaviors (Becker & Maiman, 1975; Conner & 
Norman, 2005; Leventhal & Cameron, 1987). Since the mid-seventies, behavioral studies 
have focused extensively on social psychology, more specifically on social cognition 
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models, in which an emphasis is placed on understanding human self-regulatory 
processes and mechanisms by which social cognitive processes influence peoples’ health 
behaviors (Conner & Norman, 2005). Self-regulation processes have been defined as 
“mental and behavioral processes by which people enact their self-conceptions, revise 
their behavior, or alter the environment so as to bring about outcomes in it in line with 
self-perceptions and personal goals” (Fiske & Taylor, 1991, p. 181).  
 Conceptual framing for many of the health behavior models and theories 
reviewed are very similar and their constructs are deeply intertwined (Conner & Norman, 
2005; Rothman, 2000). Their relevance to the state of the science in relation to 
understanding initiation and maintenance of T2DM self-care behaviors will be reviewed.  
The Health Belief Model 
 The Health Belief Model (HBM) is one of the first and most widely used of the 
social cognition models (SCM) (Rosenstock, Strecher & Becker, 1988). Some social 
psychologists contend that the HBM is more of a loose association of variables than an 
actual formal model to predict health behavior (Conner, 1993; Rothman, 2000). The two 
major tenets related to individuals’ representations of health proposed by the HBM are: 
(1) perceptions of illness threat and (2) evaluation of methods to counteract this threat 
(Conner & Norman, 2005). Perceptions of illness threat are influenced by domains of 
perceived susceptibility to the illness and perceived severity of the consequences of that 
illness, while evaluation methods to counteract threat involve consideration of the cost-
versus-benefit of and barriers to taking action to reduce or extinguish the perceived 
threat. Together, these two precepts are believed to determine the likelihood of a person 
engaging in healthy behaviors mediated, of course, by demographic factors, individual 
personality traits, and social pressure (Rosenstock et al., 1988). Motivation and cues to 
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action also serve as mediators for health behaviors in this model although some experts 
observe that these two constructs have been relatively ignored in most health behavior 
studies until recently (Abraham & Sheeran, 2005). 
 The ability of the HBM to explain the variance in diabetes regimen adherence and 
glycemic control in type 2 diabetes has been inconsistent and disappointing (Harvey & 
Lawson, 2009). A study by Wooldridge et al. (1992) tested the major domains of the 
HBM and its relationship to diabetes self-care adherence and metabolic control using 
measures designed by other researchers based on major concepts of the HBM (Givens, 
Givens, Gallin & Condon, 1983; Wallston, Wallston & DeVellis, 1978). Researchers in 
the study by Wooldridge et al. (1992) observed no relationship between health beliefs and 
adherence, health beliefs and HbA1c levels, or adherence and HbA1c levels. Very small 
increases in perceived severity of diabetes scores and perceived benefits of treatment 
scores following a diabetes educational program were seen in study participants, but 
these accounted for little variance in measured diabetes outcomes.  
 Some diabetes experts have questioned the applicability of the HBM to the 
complex, multidimensional nature of T2DM for a number of reasons. First, due to the 
asymptomatic nature of early disease for many years (perhaps a decade or longer 
following diagnosis), in addition to the apparent lack of appropriate threat 
communication by health care providers regarding the seriousness of the illness, persons 
with T2DM may have a perceived misunderstanding that their diabetes is not serious 
(Perlin & Pogatch, 2006; Peyrot et al., 2005). Absence of perceived threat may translate 
into a lack of perceived benefits regarding necessary lifestyle changes, self-care practices, 
and treatment intensification to maintain glycemic control until an individual’s diabetes is 
more advanced and overtly symptomatic (Dietrich, 1996). Studies examining the 
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relationship between high perceived threat in diabetes (seriousness of disease and 
vulnerability to its effects) have been associated with low self-care compliance and 
metabolic control (Bond, Aiken & Somerville, 1992; Brownless-Duffeck et al., 1987; 
Lawson, Bundy, Lyne & Harvey, 2004). 
 Second, there is a surprising, pervasive lack of belief in the efficacy of insulin 
among health care providers managing the care of patients with T2DM, and a 
commensurate failure to communicate to patients the important role of insulin in 
controlling hyperglycemia when oral medications do not (Peyrot et al., 2005; Ziemer et 
al., 2005).  This phenomenon is prevalent across multiple countries and various health 
care settings (Nakar et al., 2007; Peyrot et al., 2005). It is therefore not surprising that 
studies based on the HBM, which purport to measure patients’ 
health beliefs surrounding perceived efficacy of insulin to treat their illness, fail to 
demonstrate  significant findings (Brietzke, 2007; Wallace & Matthews, 2000). 
 Third, emotional responses to T2DM, which are substantial, may influence or 
mediate some important domains of the HBM, such as perceived severity and cues to 
action, resulting in better regimen adherence in some patients or complete denial in others 
(Weinger, 2007). However, the HBM does not clearly address emotional response to 
illness threat and subsequent behavior (Conner & Norman, 2005; Harvey & Lawson, 
2009). Depression and diabetes distress have been identified as two potent mediators of 
effective self-care management and glycemic control, and as such, must be considered in 
any theoretical framework underpinning studies that identify predictors for effective self-
care engagement, including readiness to initiate insulin therapy (Ciechanowski, Katon, 
Russo & Hirsch, 2003; Lin et al., 2004; Polonksy et al., 2005).  
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Theory of Planned Behavior 
 The Theory of Planned Behavior (TPB), an extension of the Theory of Reasoned 
Action (TRA), contends that proximal determinants of behavior are: (1) intention to 
engage in the behavior and (2) perceived control over the behavior (Azjen, 1991; 2002). 
Intentions represent a person’s motivations in their conscious decision to engage in a 
specified behavior and the degree of effort they are willing to put forth to do so. 
Perceived behavioral control is the person’s assessment of whether he or she is capable of 
performing the behavior and is most closely associated with Bandura’s (1977; 1982) 
construct of self-efficacy described in his Social Cognitive Theory (SCT). Difficulty of 
the behavior, as proposed by the TPB, is not dichotomous, but rather best conceptualized 
as a continuum of progressively more difficult behaviors to execute, according to Azjen 
(2002). Behavioral intention is determined by attitudes toward the behavior (an overall 
evaluation of the behavior by the subject), subjective norms (what the subject feels 
significant others, spouse, health care provider thinks he or she should do), and  
perceived behavioral control (how easy or difficult a behavior is to execute).  
 Effective self-care in T2DM requires the person to perform a series of 
complicated skills, daily self-monitoring activities, and complex behavioral changes 
(Anderson & Funnell, 2000; Weinger, 2007; Whittemore, 2000). The TPB has not been 
used extensively in studies of diabetes in general, and T2DM specifically, for predicting 
intention to perform self-care behaviors (Conner & Norman, 2005; Harvey & Lawson, 
2009). However, a small study of 64 type 1 diabetics demonstrated that a TPB-based 
model was able to predict 57% of the variance in subjects maintaining self-monitoring of 
their blood glucose (Shankar, Conner & Bodansky, 2007). Monitoring of blood glucose is 
a relatively easy maintenance behavior to execute and the sample was very small. 
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Therefore, findings from the study must be interpreted cautiously. An earlier study of 
type 1 diabetics, also using the TPB, revealed that positive attitude was the strongest 
predictor of self-care, and that knowledge and low orientation to powerful others 
mediated positive attitude (de Weerdt, Visser, Kok & van der Veen, 1990).  
 Critics of the TPB assert that behavioral intention does not always translate into 
action, which may be influenced by multiple factors, as is the case in T2DM (Harvey & 
Lawson, 2009). Another criticism of this theoretical approach is that there is no 
distinction between decisions regarding initiation of a behavior and subsequently 
maintaining that behavior over time, which is paramount in diabetes self-management, 
particularly in relation to insulin therapy (Rothman, 2000). Some suggest that a person’s 
prior behavior may be a better predictor of continued action, rather than current attitude 
or intentions regarding the behavior (Deci, Egharari, Patrick & Leone, 1994). Finally, the 
influence of social norms on persons with T2DM has been found in some cases to have 
the opposite effect on behavior than the TPB purports. In a study by Broom and 
Whittaker (2004), type 2 diabetics developed unhealthy defensive strategies in response 
to the intense scrutiny and criticism of their significant others and health care providers, 
rather than adopting proactive self-care behaviors.  
Social Cognitive Theory 
  Bandura’s (1977; 1982) Social Cognitive Theory (SCT) is arguably the most 
prominent theoretical framework used in studies related to self-care in T2DM. This 
approach theorizes that human motivation and action are based on three contingencies 
and that there is an implied causal ordering of these contingencies. The first contingency 
is known as situation-outcome expectancy, which represents personal beliefs about 
susceptibility to health threats. The second is action-outcome expectancy, which 
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represents an evaluation of whether a behavior will or will not lead to a particular desired 
outcome. The third is self-efficacy contingency, which represents the belief that a 
behavior or action is or is not under the individual’s control. It is the latter of these three 
constructs, self-efficacy (SE), which has served as a conceptual framework for multiple 
behavioral intervention studies related to diabetes self-care. 
 According to Bandura (1977), the concept of perceived SE holds a pivotal role in 
the causal structure of SCT. Self-efficacy beliefs influence whether people act in ways 
that are self-enhancing or self-hindering. It is belief in one’s SE that determines what 
challenges individuals will undertake, how much effort they will put forth, and how long 
they will persevere in accomplishing those challenges. Bandura (2001) also emphasizes 
that SE beliefs directly guide and shape the course one’s life takes by influencing the 
types of activities and environments in which he or she chooses to engage, such as health 
behaviors. Once engaged in health-enhancing behaviors, the social influences and 
environment must be conducive to reinforcing and promoting competencies, values, and 
interests of the individual (Kirchbaum, Aarestad & Buethe, 2003).  
 Researchers have extensively investigated the phenomenon of diabetes self-
efficacy (DSE) in conjunction with a closely-related construct known as empowerment, 
in order to devise strategies to strengthen perceived DSE in persons with T2DM; the 
ultimate goal being improved diabetes self-care competence and by extension, improved 
diabetes outcomes (Anderson et al., 1995; Anderson & Funnell, 2000; Anderson, Funnell, 
Fitzgerald & Marrero, 2000; Anderson et al., 2009; Cherrington, Wallston & Rothman, 
2010; Wallston, Rothman & Cherrington, 2007). Empowerment is the concept of 
“helping patients discover and develop the inherent capacity to be responsible for one’s 
life” (Funnell & Anderson, 2004, p. 124). Empowerment insinuates collaboration 
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between healthcare providers and patients, while creating an autonomy-supportive 
environment in the clinical setting (Williams, Freedman & Deci, 1998).  
 Results of the various studies reviewed, exploring the theoretical application of 
SE and empowerment, have strongly supported the construct of SE as an integral 
underpinning for understanding diabetes self-care behavioral initiation and maintenance. 
Anderson and colleagues’ (2009) two-year research trial that involved implementation of 
a diabetes empowerment intervention demonstrated significant increases in participants’ 
diabetes quality of life, perceived DSE, perceived understanding of their disease, and 
satisfaction with their diabetes care than those not receiving the intervention. Most 
importantly, subjects in the empowerment intervention had significantly improved 
glycemic control of their diabetes over this two-year period.  
 As a central construct of SCT, perceived SE plays an important role in an 
individual’s ability to carry out the necessary daily self-care behaviors related to T2DM 
is well-supported in various studies, but it does not explicate the determinants of 
behavioral motivation in type 2 diabetics who exhibit high self-care competency versus 
those who exhibit low competency. Why are some patients empowered through 
interventions, while others are not? Many psychologists argue that psychological needs 
play an important role in motivation and patient outcomes (Anderson, Chen & Carter, 
2000; Williams et al., 2009).     
Self-Determination Theory 
 Self-efficacy and empowerment are corresponding constructs of an approach to 
human motivation and personality known as Self-Determination Theory (SDT) (Ryan & 
Deci, 2000). The major premise of SDT posits that humans are motivated toward 
physical and psychological health. Self-motivation and personality integration are driven 
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by three basic needs, all of which are impacted by social factors: competence 
(synonymous to self-efficacy), relatedness (needs satisfaction and congruence with self), 
and autonomy (similar to empowerment). According to this theory, motivations are either 
autonomous (intrinsic) or controlled (extrinsic). Intrinsic motivation produces greater 
positive consequences and is associated with engagement in behaviors that are of the 
most interest to an individual. Behaviors emanating from autonomous motivation are 
more likely to yield long-term persistence of those behaviors (Vallerand, 2001; Williams, 
Rodin, Ryan, Grolnick & Deci, 1998).  
 Motivation, whether intrinsic or extrinsic, is theorized to take place within the 
individual at three hierarchical levels: global, contextual, and situational (Ryan & Deci, 
2000; Vallerand, 2001). Global motivation is conceptualized as an individual’s overall 
personality orientation toward intrinsic or extrinsic motivation. Contextual motivation 
refers to domain-specific orientations such as education, interpersonal relationships, or 
inner needs. Finally, situational motivation is primarily a “state” motivation, such as 
living with a chronic disease, for example. An autonomy-supportive environment, 
whether originating from family, friends, or healthcare providers, fosters intrinsic 
motivation. Intrinsic motivation is also referred to as autonomous self-regulation, wherein 
the individual experiences a sense of volition in performing the behavior for the inherent 
satisfaction of the activity itself (Deci, Eghrari, Patrick & Leone, 1994; Williams et al., 
1998). Conversely, those whose behavior is perceived to be controlled externally or by 
some interpersonal force (spouses, friends, or health care professionals) feel pressured to 
perform a behavior in order to satisfy an external demand or some conditional reward 
without really valuing the goal or behavior; also known as controlled self-regulation.  
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 Extrinsic motivation, which may be the predominant motivation orientation in 
self-care behaviors of persons with chronic illness, does not preclude adoption of certain 
identified regulations into the individual’s long-term behavioral repertoire. Integrated 
regulation, the most autonomous form of extrinsic motivation, is a process by which the 
individual internalizes identified goals or regulations and assimilates them to the self, 
typically in stages over time (Ryan & Deci, 2000). This process may result in a person 
adopting a behavior if that behavior is perceived to have related importance to them and 
if it can be brought into congruence, or synthesis, with the individual’s goals and values.  
 Behavioral regulations may be internalized at any point in time, but are theorized 
to be heavily influenced by prior experiences, knowledge, and current situational factors 
(Deci et al., 1994). Ryan and Deci (2000) also assert that the range of internalized 
behaviors or goals that an individual assimilates over time increases as a function of his 
or her perceived competence in being able to perform an identified behavior and whether 
that behavior has goal relatedness: meaning the behaviors are either valued by the 
individual or they are valued by one’s significant others or peer group. In fact, some 
research has shown that reciprocal peer support among type 2 diabetics can significantly 
increase rates of insulin initiation or intensification of insulin therapy; suggesting that an 
individual’s concerns about insulin are most effectively addressed by other individuals 
coping personally with insulin management (Heisler, Vijan, Makki & Piette, 2010). 
 Research that has applied SDT as a framework has thus far yielded some 
convincing evidence for supporting its use as a framework in future studies targeting 
modifiable factors to improve self-care in T2DM and glycemic control. A previous study 
by Heisler and colleagues (2003) demonstrated that the stronger the individual’s belief in 
the efficacy of their prescribed treatments and the more autonomy-supportive the clinical 
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environment was perceived to be, the stronger the concordance between the provider’s 
and patient’s goals. In addition, the study showed that greater agreement between patient 
and provider goals led to significant increases in the patient’s perceived diabetes 
competence and reported autonomous self management. Another study found that 
patients who rated their diabetes care providers as affording them a high autonomy-
supportive environment had significant increases in autonomous motivation and 
perceived diabetes self-care competence (Williams, McGregor, Zeldman, Freedman & 
Deci, 2004). Subjects in that study who exhibited high autonomous motivation and high 
perceived competence also manifested significantly lower HbA1c levels. Patients’ HbA1c 
levels have been shown to correspond to more effective diabetes self-care practices 
(ADA, 2003). A later study by Williams and his colleagues (2009) applied the SDT 
model of health behavior to predict medication adherence, quality of life, and glycemic 
control in a sample of type 2 diabetic adults. All three outcomes were positively 
associated with a perceived autonomy-supportive environment and perceived competence 
for diabetes self-management.           
Self-Determination Theory and Readiness to Initiate Insulin Therapy 
 After review and evaluation of theoretical frameworks that have been used to 
study self-care behaviors in T2DM, it appears that SDT may provide the most appropriate 
framework for exploring factors that predict readiness to initiate insulin therapy when 
oral therapy has failed to control hyperglycemia in T2DM. This framework incorporates 
constructs that address critical factors influencing decisions to initiate new self-care 
behaviors, as well as maintain those behaviors over time, in persons with T2DM. Self-
care competency, autonomous self-care agency, and autonomy-supportive collaboration 
with one’s health care provider are all modifiable factors within a paradigm of diabetes 
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care that enhances volitional integration of self-care regulation in patients, rather than 
focusing solely on the products of medical care, such as adherence and compliance, 
which are dehumanizing and counterproductive in changing behavior (Anderson & 
Funnell, 2000, 2005).  
 A conceptual model has been developed to illustrate the relationship of the study 
variables of interest to the major constructs of SDT and it is depicted in Figure 3.1. The 
overarching goal of research using this model is to identify modifiable variables that may 
predict increased readiness to initiate insulin therapy when hyperglycemia is no longer 
controlled by oral anti-diabetic agents in T2DM. According to SDT, autonomy support 
encourages persons’ autonomous self-regulation and perceived competence for 
engagement in diabetes self-care behaviors. In testing major constructs of SDT through 
biobehavioral research, the adoption of insulin therapy in individuals with T2DM 
unresponsive to oral therapy is the self-care regulation of interest and readiness of 
individuals to initiate insulin therapy is the outcome variable. Several measures have 
been developed and used to test major constructs of SDT, but have yet to be studied with 
respect to the proposed outcome variable: readiness to initiate insulin therapy. 
Perceived Autonomy Support 
 Although initiation of insulin therapy may be a high-priority goal of the provider, 
the priority of insulin therapy as an internalized goal of the patient must also be 
determined. Heisler and her colleagues (2003) demonstrated that diabetic patients who 
reported sharing greater responsibility with their health care provider in making treatment 
decisions were significantly more likely to be in agreement with the provider’s priority 
goals for treatment. Therefore measuring patients’ perceptions of the degree to which 
their health care provider provides an autonomy-supportive environment will be 
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important in determining its predictive value in patients’ readiness to initiate insulin 
therapy.  
 The Health Care Climate Questionnaire (HCCQ) is a psychometric tool that was 
developed to evaluate the patient’s perceptions of the degree to which their health care 
provider is autonomy supportive (Heisler et al., 2003; Williams, Freedman, et al., 1998; 
Williams et al., 1998; Williams et al., 2009). The HCCQ has been shown to be a valid 
and reliable (α = 0.80 to 0.96) measure of perceived autonomy support. Subjects rate their 
response to each of the 15 questions using a 7-point Likert scale (1 = “strongly disagree” 
to 7 = “strongly agree”). Scores range from 15 to 105 with higher scores indicating more 
equally-shared decision making between the patient and health care provider, provider 
trust, and perceived respect from the provider.  
Perceived Behavior Competence 
 Patients’ perceived competence in being able to perform a behavior is an essential 
theoretical construct of SDT because it facilitates an individual’s goal attainment and 
provides him or her with a sense of need satisfaction from engaging in an activity at 
which they feel effective. Perceived competence has been well-supported in multiple 
studies as an important predictor of agent-driven behaviors related to diabetes self-care 
success (Anderson et al., 1995; Anderson et al., 2000; Heisler et al., 2003; Kirchbaum et 
al., 2003; Norris et al., 2001; Williams et al., 2009).  
 Diabetes self-care management is complex and demanding for any patient. 
Beginning insulin therapy and adopting the increased self-monitoring, surveillance, and 
planning that is required in order to avoid adverse effects, especially early in the course 
of therapy, requires self-perceived efficacy in those behaviors and skills (Rosenstock & 
Riddle, 2004; van der Ven et al., 2003). Measuring subjects’ perceived overall 
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competence for diabetes management will be necessary in order to evaluate whether this 
variable is a predictor for readiness to start insulin therapy in T2DM. It would be logical 
to reason that if overall diabetes competency is low, then readiness to begin a more 
complex behavior, such as insulin therapy, would also be low.   
 The Perceived Competence in Diabetes Scale (PCDS) is a psychometric 
instrument which was developed to evaluate the patient’s perceptions of his or her 
confidence in performing diabetes self-care. The PCDS is a four-item scale that has been 
shown in various studies to be a valid and reliable (α = 0.80 to 0.88) measure of this 
construct (Heisler et al., 2003; Williams et al., 1998; Williams et al., 2009). Subjects rate 
their confidence in performing diabetes self-care using a 7-point Likert scale for each 
question (1 = “not at all true” to 7 = “very true”). Scores range from four to 28, with 
higher scores indicating greater perceived confidence.    
Autonomous Versus Controlled Regulation of Behavior 
 The degree to which a person’s motivation for health behaviors is autonomous is 
another major construct of SDT. Goals of diabetes treatment, or self-regulations, must be 
internalized and assimilated to the self in order for the person to experience maximum 
autonomy in diabetes self-management. For behavioral integration and volitional 
persistence of a particular self-regulation, for example using insulin therapy, it must be 
synthesized within the individual’s behavioral repertoire (Deci & Ryan, 2000). Synthesis 
is more likely to occur if the individual perceives insulin as personally important, the 
behavior of using insulin is consciously valued, and there is a perception of insulin 
therapy being congruent with the situational context of his or her illness (Deci et al., 
1994). Therefore motivation orientation of type 2 diabetic patients must be assessed in 
order to determine its influence on subjects’ readiness to start insulin.  
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 The Treatment Self-Regulation Questionnaire (TSRQ) was developed to measure 
the motivation orientation of individuals. The TRSQ has demonstrated both validity and 
reliability (α = .90) in measuring aspects of autonomous versus controlled regulation of 
behavior in studies with type 2 diabetic patients (Williams et al., 1998; Williams et al., 
2009). It contains 19 statements in which subjects rate their agreement with each using a 
7-point Likert scale (1 = “not at all true” to 7 = “very true”). The TSRQ is comprised of 
two subscales: the autonomous regulation subscale that measures intrinsic motivation 
orientation and the controlled regulation subscale that measures extrinsic motivation 
orientation. In order to determine an individual’s dominant motivation orientation, a 
relative autonomy index (RAI) score is derived by subtracting the average autonomous 
subscale score from the average controlled subscale scale score (Williams et al., 1998). 
Higher RAI scores indicate a greater autonomous motivation orientation. 
Beliefs and Attitudes Associated with Insulin Therapy 
 Snoek and colleagues developed the Insulin Treatment Appraisal Scale (ITAS) to 
measure beliefs and attitudes associated with insulin therapy in diabetic patients (Snoek, 
Skovland & Pouwer, 2007). This instrument has been useful for identifying negative 
feelings and misconceptions that diabetic patients have regarding insulin therapy (Snoek 
et al.; Makine et al., 2009).  The ITAS has been shown to be a valid and reliable (α = .82 
to .90) measure of patients’ beliefs and attitudes related to insulin therapy (Makine et al., 
2009; Snoek et al.). It is appropriate to use with patients contemplating insulin therapy 
initiation as well as those who are currently using insulin therapy. 
 The ITAS contains 20 statements regarding common beliefs and attitudes related 
to insulin therapy in which subject’s rate their agreement with each statement using a 5-
point Likert scale (1 = “strongly disagree” to 5 = “strongly agree”). Four of these 
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statements are positively-worded and reverse-scored before totaling and 16 are 
negatively-worded. Lower total scores on the ITAS indicate more positive or favorable 
attitudes and beliefs regarding insulin therapy.  
Enhancing Readiness to Initiate Insulin Therapy 
 Motivation toward authentic self-regulation is a complex construct influenced by 
many individual variables and contextual factors (Ryan & Deci, 2000). It is important to 
understand conditions or circumstances that may potentially encourage rather than 
discourage intrinsic motivation of type 2 diabetics in a therapeutic clinical setting. It has 
been shown that support of authentic, autonomous self-regulation produces the 
committed self-care behaviors that health care providers desire for their patients (Ryan & 
Deci; Williams et al., 1998; Williams et al., 2009). Building competence in an autonomy-
supportive care environment is essential for facilitating intrinsic self-regulation in 
patients with chronic illnesses who are required to perform numerous, complicated, and 
often unpleasant self-care behaviors (Anderson & Funnell, 2000; Williams et al., 2005).  
 Discussions between providers and their patients regarding initiation of insulin 
therapy are heavily value-laden (Hunt, Valenzuela & Pugh, 1997; Peyrot et al., 2005). 
Perceived insinuations of failure in managing one’s diabetes and worsening disease are 
not uncommon among patients with T2DM. Consequently it is important to understand 
the effects of psychosocial contexts, patient-provider relationships, motivational 
orientation, and attitudes towards insulin on a diabetic patient’s readiness to begin insulin 
therapy when it becomes necessary to do so for effective control of hyperglycemia. Self-
determination theory appears to address these myriad influences on a patient’s decision to 
adopt insulin therapy and persevere with the self-care behavior required.   
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Conclusion 
 In conclusion, SDT provides a promising theoretical framework for investigating 
factors that may predict readiness of patients with T2DM to initiate insulin therapy when 
their current self-regulations are not effectively controlling their hyperglycemia. Because 
the decision to begin insulin therapy is difficult for most patients, especially those 
diabetic patients who currently “feel fine” yet have chronic poor glycemic control, 
identification of modifiable influencing factors that can make this transition smoother is 
necessary. Through better understanding of psychosocial factors, individual needs, and 
personal motivations related to adoption of insulin therapy in persons with T2DM, health 
care providers may find their discussions with patients to be easier to initiate much earlier 
in the course of their disease.  
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Figure 3.1. Conceptual model linking constructs of Self-Determination Theory to main study variables. 
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CHAPTER FOUR 
Predictors of Readiness to Initiate Insulin Therapy in Patients with Type 2 Diabetes 
When Oral Medications Fail to Control Hyperglycemia 
OBJECTIVE: The objective of this study was to use Self-Determination Theory (SDT) 
as a framework for identifying modifiable predictors of readiness to initiate insulin 
therapy when oral medications fail to control hyperglycemia in patients with type 2 
diabetes (T2DM). Specifically, the aim was to determine if perceived autonomy-support, 
perceived diabetes competence, motivational orientation, and appraisal of insulin therapy 
were predictors of readiness to initiate insulin therapy in persons with T2DM when oral 
therapy fails to control hyperglycemia.  
DESIGN: Descriptive correlational study using cross-sectional data collection methods. 
SETTING: Adult medical clinics of large urban primary healthcare facilities in 
Southwest Ohio and Northern Kentucky.  
PARTICIPANTS: Adult patients (n = 73) with T2DM using only oral antidiabetic 
medications for their diabetes. 
METHODS: Data for demographic characteristics, pertinent clinical information, 
exposure to insulin therapy, psychometric measures of perceived autonomy-support 
(HCCQ), perceived diabetes competence (PCDS), motivational orientation (TSRQ), and 
appraisal of insulin therapy (ITAS), and readiness to initiate insulin therapy were 
collected on each person.  
RESULTS: Bivariate logistic regression revealed two significant predictors of readiness: 
(1) participants who had a friend or family member using insulin therapy were 5.5 times 
more likely to rate their readiness to initiate insulin as high compared to those who had 
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neither and (2) for each unit increase in ITAS score participants were 8.4 % more likely 
to rate their readiness as low. 
CONCLUSION: Exposure to friends or family using insulin and negative appraisal of 
insulin therapy are significant predictors of readiness to initiate insulin for patients with 
T2DM. 
KEY WORDS:  Self-Determination Theory; insulin readiness; autonomy-support; type 2 
diabetes 
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Introduction 
 Type 2 diabetes mellitus (T2DM) has become a public health crisis, not only in 
the U.S., but also worldwide. Nearly 26 million people in the U.S. alone are affected by 
diabetes, 90% to 95% of which is T2DM (National Diabetes Information Clearinghouse 
[NDIC], 2010). The burden of diabetes also presents a crisis in terms of health care costs, 
both direct and indirect. Direct medical expenditures were estimated to be $116 billion in 
2007 while indirect costs from disability, work loss, and premature death were an 
additional $58 billion (NDIC). Future costs have been projected to escalate exponentially. 
By 2034, diabetes costs are expected to reach an estimated $336 billion in direct 
healthcare expenditures (Huang, Basu, O’Grady & Capretta, 2009).     
 Diabetes increases risk of stroke and death from heart disease to rates two to four 
times those of nondiabetics (NDIC, 2011). Diabetes is also the leading cause of new 
cases of blindness, kidney disease, and nontraumatic lower limb amputations (NDIC). 
This morbidity is associated with double the risk for depression in this population 
(Anderson, Freedland, Clouse & Lustman, 2001). Experts suggest that clinicians should 
discard the notion that diabetes is simply a disease of hyperglycemia, and instead regard 
and treat diabetes as a more global vascular disease that includes treatment interventions 
that address abnormal glucose levels, dyslipidemia, inflammatory endothelial 
dysfunction, and accelerated atherosclerosis (Mirza, 2007). Clinicians must also 
understand and communicate clearly to patients that T2DM is a progressive disease. 
Informing patients at the time of diagnosis, that even in the face of optimal glycemic 
management in the initial phase of treatment, β-cell function and physiologic insulin 
response will continue to erode over time to the point at which exogenous insulin 
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administration will be necessary in many cases (Barag, 2011; Harris, Kapor, Lank, 
Willan & Houston, 2010).  
  Clinical knowledge, published treatment guidelines, and the therapeutic arsenal 
for controlling T2DM are extensive (Cefalu, Richards & Menendez-Ramirez, 2009; 
Mirza, 2007). Despite these achievements, poor control of hyperglycemia remains a 
significant problem in the medical management of T2DM largely due to the underuse or 
inappropriately delayed use of insulin (Peyrot et al., 2005). Both reluctance of patients to 
use insulin and healthcare-provider clinical inertia in initiating insulin therapy, have been 
identified as major underlying components of this problem (Harris et al.; Kunt & Snoek, 
2009; Reach, 2008).  Even clinicians who intend to prescribe insulin for their patients 
with type 2 diabetes struggle to determine when patients are ready to consider it. The 
objective of this study was to use Self-Determination Theory as a framework to identify 
modifiable predictors of readiness to initiate insulin therapy when oral medications fail to 
control hyperglycemia in patients with T2DM. Specifically, the aim was to determine if 
perceived autonomy-support, perceived diabetes competence, motivational orientation, 
and appraisal of insulin therapy predicted readiness to initiate insulin therapy in persons 
with T2DM when oral therapy fails to control hyperglycemia. 
Clinical Inertia, Non-adherence, and Type 2 Diabetes Care 
Clinical inertia on the part of health care providers to initiate insulin therapy and 
reluctance or resistance on the part of patients to embrace insulin therapy as part of their 
treatment regimen are common reasons that contribute to the underuse of insulin in the 
management of T2DM (Grant et al., 2007; Harris et al., 2010; Peyrot et al., 2005; Ziemer 
et al., 2005). Perhaps one of the most problematic factors contributing to clinical inertia 
of health care providers identified during investigations of this phenomenon are the 
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negative attitudes held by diabetes practitioners regarding their perceptions of patients’ 
nonadherence to self-care practices. A study by Drass and colleagues (1998) surveyed 
370 primary care providers who managed diabetic care and found that time and expense, 
complexity of diabetes care, and lack of clear care guidelines were barriers to effective 
care. In addition, providers rated patients’ nonadherence to treatment as the most 
frustrating and problematic barrier to glycemic control.  
A subsequent prospective cohort study of 2,065 patients with type 2 diabetes by 
Grant, Buse and Miegs (2005) highlights the important relationship linking patient 
behavior (adherence) and physician action (intensifying diabetes therapy). Researchers in 
this study found that patients in the highest baseline medication adherence quartile had 
53% greater odds of having their therapy intensified (including initiation of insulin 
therapy) relative to rising A1C than compared to those patients in the lowest quartile. 
Perceived poor adherence patterns may therefore doom some patients to inadequate 
management of their hyperglycemia due to their provider’s negative attitudes and 
frustration toward misunderstood behaviors related to self-care regulation in these 
patients. 
 Adherence to medication regimens is problematic in all patients with chronic 
illnesses and diabetes is no exception. Diabetic patients require rationale for 
intensification of treatment therapies, adequate time to discuss their diabetes regimen and 
changes with their healthcare provider, shared decision-making opportunities and 
ongoing support from primary care providers in order to foster effective self-care 
practices in this population of patients, particularly with regard to adoption of insulin 
therapy (Anderson & Funnell, 2000). It is therefore important to identify factors that may 
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increase patients’ willingness and readiness to initiate insulin therapy when conservative 
treatment regimens fail to adequately control their T2DM.  
Theoretical Framework 
Self-Determination Theory, Diabetes Self-Care, and Insulin Therapy 
 The concept of treatment compliance, or adherence, emerged from a health care 
paradigm representing a time when the majority of illnesses and diseases were acute in 
nature (Anderson & Funnell, 2000). This paradigm promulgates the notion that health 
care providers must assume the primary responsibility for ensuring that their patients 
engage in the prescribed treatments. In addition, this view presupposes that the health 
care provider controls a patient’s self-management decisions and engagement in optimal 
diabetes self-care activities. Anderson and Funnell (2005) argue that under this acute-care 
paradigm, patients who fail to perform to the provider’s expectations are labeled as 
noncompliant or nonadherent, which eventually leads to the development of 
dysfunctional and corrosive relationships between providers and patients.  
Leading experts in diabetes care believe that patients with diabetes are fully 
responsible for the course and outcomes of their illness, because the most important 
choices affecting the health and well-being of the person with diabetes are made by those 
with the disease, not their health care provider or diabetes educator (Anderson & Funnell, 
2000; Funnell & Anderson, 2004; Steed, Cooke & Newman, 2003; Weinger, 2007). 
Eliminating the concepts of compliance and adherence, which undermine the patient-
provider relationship, from diabetes care involves incorporating a truly collaborative 
model between health care providers and their patients that maximizes patient autonomy. 
This will mean abandoning assumptions of power, control, judgment, and blame on the 
part of the health care provider, while instead empowering patients to choose and 
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experiment with self-care interventions in deciding what works best for them in 
managing their diabetes in everyday life (Anderson et al., 2009; Anderson & Funnell, 
2000; Barlow, Wright, Sheasby, Turner & Hainsworth, 2002). In fact, patients’ perceived 
competence has been well-supported as an important predictor of agent-driven behaviors 
related to diabetes self-care success in multiple studies (Anderson et al., 2009; Anderson, 
Funnell, Fitzgerald & Marrero, 2000; Kirchbaum, Aarestad & Buethe, 2003; Norris, 
Engelau, Naryan, 2001; Williams et al., 2009). 
Self-efficacy and empowerment are parallel constructs of a behavioral approach 
to human motivation and personality known as Self-Determination Theory (SDT) (Ryan 
& Deci, 2000). The major premise of SDT posits that humans are motivated toward 
physical and psychological health. Self-motivation and personality integration are driven 
by three basic needs, all of which are impacted by social factors: competence (similar to 
self-efficacy), relatedness (needs satisfaction and congruence with self), and autonomy 
(similar to empowerment). According to SDT, motivations are either autonomous 
(intrinsic) or controlled (extrinsic). Intrinsic motivation produces the most positive 
behavioral outcomes because they are generally of the most interest to the individual. 
Behaviors emanating from autonomous motivation (self-agency) are more likely to yield 
long-term persistence of those behaviors (Vallerand, 2001; Williams, Rodin, Ryan, 
Golnick & Deci, 1998).  
Prior studies based on SDT have demonstrated that the stronger the individual’s 
belief in the efficacy of their prescribed treatments and the more autonomy-supportive the 
clinical environment was perceived to be, the stronger the agreement between provider’s 
and patient’s shared goals (Heisler et al., 2003). Likewise, greater agreement between 
patient and provider goals led to significant increases in the patient’s perceived diabetes 
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competence and reported autonomous self-management. Another study found that 
patients who rated their providers as providing a high autonomy-supportive environment 
had significant increases in autonomous motivation and perceived diabetes self-care 
competence (Williams, McGregor, Zeldman, Freedman & Deci, 2004). Subjects that 
exhibited high autonomous motivation and high perceived competence also manifested 
significantly lower A1C levels, which have been shown to correspond to more effective 
diabetes self-care practices. A later study by Williams et al. (2009) applied the SDT 
model of health behavior to predict medication adherence, quality of life, and glycemic 
control in a sample of type 2 diabetic adults. All three outcomes were positively 
associated with a perceived autonomy-supportive environment and perceived competence 
for diabetes self-management. 
 Because prior studies based on a SDT framework have not focused specifically on 
insulin initiation, a study that explores the influence of competence, relatedness, and 
motivational orientation on a type 2 diabetic person’s perceived readiness to begin insulin 
therapy when oral therapy fails is necessary if the model of diabetes care is to change and 
glycemic control is to be achieved. In addition to testing major constructs of SDT, 
determining the contribution of attitudes and beliefs regarding insulin therapy in relation 
to these constructs will also be important as prior studies have found patients’ appraisal 
of insulin to play a significant role in their willingness to adopt insulin therapy and 
believe in its efficacy as a treatment for T2DM (Makine et al., 2007).  
Methods 
Design 
 The study used a descriptive correlational design via cross-sectional data 
collection. Data for this study were collected using a questionnaire format. Purposive 
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sampling of type 2 diabetic patients currently using oral medications to control their 
diabetes was used.  
Sample and Setting 
 A total of 73 study participants were recruited from primary care offices and 
ambulatory outpatient clinical facilities in Southwest Ohio and Northern Kentucky.  
Primary care sites were targeted specifically because insulin initiation and management 
for T2DM is becoming increasingly more frequent in primary care and it is in this setting 
that clinical inertia has been demonstrated to be most problematic (Hayes, Fitzgerald & 
Jacober, 2008; Kunt & Snoek, 2009; Hsu, 2009). Participants were recruited primarily 
from the adult medical clinics in an urban primary care health facility with two locations 
in Southwest Ohio (n = 65). The medical director and his physician colleagues agreed to 
participate fully in the study and allowed access to their patients scheduled each day in 
clinic. This institution has been designated as a federally qualified health center (FQHC) 
and its patients are predominantly African American. A few participants were also 
recruited from an internal medicine practice located in an outpatient facility in Northern 
Kentucky (n = 8). The sample size was based on a power analysis to ensure sufficient 
power for the study (α = .85, p = .05, one-tail). Patients were recruited between June 
2011 and October 2011. 
Inclusion and Exclusion Criteria  
 Patients were eligible to participate in the study if they: (1) were ≥ 18 years old, 
(2) were able to speak and read English, (3) had a diagnosis of type 2 diabetes made by a 
physician or nurse practitioner using American Diabetes Association (ADA) criteria 
(Gerich, 2004), and (4) were currently being treated with oral antiglycemic agents. 
Patients were excluded if they: (1) were < 18 years old, (2) were pregnant, (3) had 
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cognitive impairment, (4) unable to speak or read English, or (5) were currently using 
insulin in addition to oral agents.  
Measurements 
 Perceived Competence in Diabetes Scale 
 Participants rated perceived competence in providing self-care for their diabetes 
using the Perceived Competence in Diabetes Scale (PCDS). They responded to each of 
the four statements by rating their agreement on a 7-point scale that range from 1 “not at 
all true” to 7 “very true”. Scores can range from four to 28. Higher scores indicate greater 
perceived competence in diabetes self-care (Williams, Freedman & Deci, 1998). 
 Health Care Climate Questionnaire 
 Participants were asked to respond to 15 statements regarding various aspects of 
their interactions with, trust in, and shared decision-making with the healthcare provider 
treating them for their diabetes. The Health Care Climate Questionnaire (HCCQ) was 
developed to capture the degree of perceived autonomy in patient-provider decision-
making process regarding the clinical management of chronic illnesses. Participants rated 
their agreement with each of the statements on a 7-point scale that range from 1 “strongly 
disagree” to 7 “strongly agree”. Scores can range from 15 to 105. Higher scores indicate 
a greater autonomy-supportive environment (Williams, Freedman & Deci, 1998; 
Williams et al., 1998).  
 Treatment Self-Regulation Questionnaire  
 Participants were asked to respond to 19 statements representing motivations for 
performing different aspects of diabetes self-care. The Treatment Self-Regulation 
Questionnaire (TSRQ) contains two subscales: autonomous regulation scale (8 questions) 
and controlled regulation scale (11 questions). Participants rated their agreement with 
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each of the 19 statements using a 7-point scale that ranged from 1 “not true at all” to 7 
“very true”. Subscale scores were then averaged. A relative autonomy index (RAI) score 
was derived for each participant by subtracting their controlled regulation subscale 
average from the autonomous regulation subscale average. Higher RAI scores indicate 
greater autonomous motivational orientation (Williams, Freedman & Deci, 1998; 
Williams et al., 1998).  
 Insulin Treatment Appraisal Scale  
 Participants were asked to respond to 20 statements representing beliefs and 
attitudes about insulin. The Insulin Therapy Appraisal Scale (ITAS) was developed to 
capture the T2DM patient's current appraisal of insulin therapy and assesses both positive 
and negative attitudes (Snoek, Skovlund & Pouwer, 2007). Participants were asked to 
indicate on a 5-point Likert scale to what extent he or she agrees with each statement, 
from 1"strongly disagree” to 5 “strongly agree”. The four positive statements are 
reversed-scored before totaling. Scores can range from 20 to 100. Lower scores represent 
more positive attitudes and beliefs about insulin therapy. This scale has been shown to be 
a valid measure in patients contemplating insulin therapy as well those currently using 
insulin therapy (Hermanns, Mahr, Kulzer, Skovlund & Haak, 2010; Larkin et al., 2008; 
Makine et al., 2007).  
 Readiness to initiate insulin therapy 
 In order to measure the outcome variable, readiness to initiate insulin therapy, 
participants were asked to consider a situation in which their blood glucose was not being 
effectively controlled with oral antidiabetic agents and that insulin was considered by 
their health care provider to be an alternative medication that would effectively bring 
their blood glucose levels under better control. They were then asked to rate how soon 
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they would be ready to initiate insulin therapy. Choices ranged from 0 (representing 
immediate readiness) to 12 months (representing indeterminate readiness). This variable 
was dichotomized into the following categories of readiness for purposes of analysis: 
high readiness (≤ 3 months) was represented by choices 0, 1, and 3 months and low 
readiness  (≥ 6 months), represented by choices 6, 9, and 12 months on the questionnaire.  
 Measurement of other variables of interest 
 Demographic and clinical data were collected to fully describe and characterize 
the subjects, as well as account for possible confounders. Demographic variables 
included age, race, gender, whether or not the participant lived alone or with someone, 
education, income level, and type of insurance. Clinical variables included number of 
oral diabetes medications currently being taken, duration of diabetes, length of time with 
current diabetes provider, and the two most recent serum glycosylated hemoglobin 
(HbA1c) values. The HbA1c value serves as an indicator of an individual’s glycemic 
control in the 90 to 120 days preceding the lab draw (ADA, 2009). Clinicians use HbA1C 
to estimate a patient’s average serum glucose during that time period. 
  Because a patient’s attitudes and beliefs about insulin therapy may be influenced 
by prior exposure to insulin, such as someone they know uses insulin, they have injected 
insulin for someone else, or they have discussed insulin with their provider, four 
additional questions of interest were included on the questionnaire (Kunt & Snoek, 2009). 
These questions asked participants to indicate if (1) his or her primary care provider 
(PCP) had discussed the eventuality of insulin therapy to treat his or her T2DM at the 
time of diagnosis, (2) his or her PCP had ever discussed using insulin at any time during 
treatment for T2DM, (3) whether or not a family member had been diagnosed with 
T2DM, and (4) whether anyone they knew (friend or family member) used insulin to treat 
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his or her T2DM. These questions were coded as either being affirmative (1) or negative 
(0).  
Procedures 
 Permission for conduct of the study was obtained from the University of 
Kentucky’s Institutional Review Board (UKIRB). Once UKIRB permission was granted, 
permission to recruit participants and conduct the study in the adult medical clinics of the 
HealthCare Connection (HCC) was obtained from the institution’s medical director and 
chief executive officer.  Concurrent IRB permission was sought from St. Elizabeth 
Medical Center (SEMC) for a secondary collection site in Northern Kentucky. 
Permission was eventually obtained but various difficulties arose during the process that 
resulted in significantly fewer patients being recruited from this site.  
 All patients with T2DM who attended the adult medical clinics of the HCC were 
given a flyer explaining the study and were invited by the medical assistant checking 
them in or by the physician during their visit to participate in the study that day. 
Interested patients were directed to an exam room located on the premises in which the 
investigator was located. Once eligibility for the study was determined, informed consent 
and permission for release of medical information were obtained by the primary 
investigator from participants. The investigator remained available to answer 
participants’ questions. Questionnaires were checked for completeness prior to 
participants leaving the study site at which time they received a ten-dollar gift card as 
compensation for their time and participation in the study. The two most recent HbA1C 
values and type of insurance were extracted from the patient’s chart and recorded on the 
front page of the questionnaire. The same procedure was followed at the SEMC site with 
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the exception that an institutional employee was required to extract the necessary medical 
information from the chart.  
Data Management and Analyses 
  Because logistic regression analysis was used, no assumptions of normal 
distribution, linearity, or equal variances regarding the distributions of predictor variables 
were considered. However, as in all types of multiple regression, logistic regression is 
sensitive to high correlations among predictor variables, therefore continuous 
independent variables were assessed for multicollinearity (Mertler & Vannatta, 2005). 
Tolerance for all these variables exceeded 0.1 indicating that multicollinearity was not a 
problem. In addition, data were examined to determine whether or not to collapse some 
categories of variables in which too few cases existed before analysis. Based on this 
examination, income was collapsed into two categories: less than $30,000/year and ≥ 
$30,000/year. Only four cases in the highest income category (> $60,000/year) were 
represented. Number of medications was collapsed into three categories: one, two, and 
three or more medications. Finally, race of participants was collapsed into two categories: 
African American and Caucasian, the latter of which included the single Latino 
participant. Complete sample characteristics were presented as either means (± SD) or 
frequencies and percentages appropriate to the level of measurement used.  
 Bivariate logistic regression was performed using the forward likelihood ratio 
(LR) method to determine which independent variables were predictors of readiness to 
initiate insulin therapy. The LR method of variable selection was used as it is one of the 
most common, yet conservative, methods of entering variables into the regression model 
(Mertler & Vannatta, 2005). All categorical variables were dummy-coded before entry 
into the regression analysis. Independent variables were entered in three blocks. Block 
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one contained the demographic variables (age, gender, race, income level, education, and 
whether or not the participant lived with someone) and clinical variables (duration of 
diabetes, number of oral antidiabetic medications, length of time with current diabetes 
provider, and average serum glucose). Block two contained the insulin exposure variables 
that included whether or not insulin was discussed as a potential therapy at diagnosis, 
insulin was ever discussed as a therapy during treatment, the patient had a family member 
with T2DM, or they knew a friend or family member using insulin. Block three contained 
the psychometric measurement variables of specific interest: PCDS total score, HCCQ 
total score, ITAS total score, and RAI score. The forward LR selection method of 
variable entry into the model designated a significance level of ≤ .05 as the cut-off value 
for entry of variables into the model.  
Results 
Characteristics of Sample 
 Seventy-three participants with T2DM were included in this study, the majority of 
which were African American (71%) and female (70%). Their mean age was 
approximately 57 ± 11.9 (range 22 to 81) with the majority being 50 years of age or 
older. Just over half of those participating in the study cohabited with someone. Average 
education level was 11 (± 2) years. Seventy-seven percent of participants earned less than 
$30,000 per year. Descriptions of the sample’s demographic characteristics can be found 
in Table 4.1. 
 More than half of participants (56%) had publicly-funded health insurance. Most 
of those participating were taking one oral antidiabetic medication (59%). The mean 
duration of diabetes was 6.5 ± 5.8 years (range 0.5 to 25). The mean value of average 
serum glucose for the sample during the preceding six months was nearly 203 mg/dl ± 
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65.3 mg/dl (range 104 to 441) which translates to a mean HbA1c value of approximately 
8.7%. The ADA (2009) recommends that patients maintain a HbA1c goal of < 7% to 
prevent serious disease sequelae from hyperglycemia. The mean number of years 
participants had been with the same diabetes care provider was 5.3 ± 5.6 (range 0.5 to 
21). The majority (69.9%) of participants had been with their diabetes care provider for 
five years or less. Clinical characteristics of the sample are described in Table 4.2. 
 The number of participants who had discussed insulin as a potential therapy for 
their T2DM at diagnosis, had ever discussed it as therapy for their T2DM, and had a 
friend or family member who used insulin were almost evenly split with those who had 
not. Two-thirds of respondents (68.5%) had a family member with T2DM. Statistics 
describing insulin exposure may also be found in Table 4.2. 
 Nearly 58% of participants (n = 42) rated their readiness to initiate insulin therapy 
as immediate. Overall 70% of the sample rated their readiness to  initiate insulin therapy 
as high (n = 51).  
Psychometric Measurement Results 
 The mean total score for the PCDS was 23.6 ± 5.2 (range 4 to 28) which was very 
close to the maximum possible score for the scale. Similarly, the mean HCCQ total score 
was 96.9 ± 10.5 (range 39 to 105), also very close to the maximum possible score for that 
scale. More variance was seen in mean scores for the ITAS and RAI. The mean total 
score for the ITAS was 57.5 ± 11.7 (range 27 to 83). The mean RAI score for the sample 
was -2.3 ± 20.1 (range -88 to 72). These results are described in Table 4.3. 
Logistic Regression Results 
 Forward logistic regression using the forward LR method was conducted in three 
blocks to determine which IVs were predictors of readiness to initiate insulin therapy. 
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Data screening revealed no extreme outliers. Demographic (age, gender, race, education, 
income, and lives with status) variables and clinical variables (duration of diabetes, 
length of time with MD, number of antidiabetic meds, and average serum glucose) were 
entered in block one. Regression results in this block indicated that one predictor, average 
serum glucose, was the only significant predictor that was statistically reliable in 
distinguishing between high and low readiness groups (-2 Log Likelihood = 84.132, 
Goodness-of-Fit = 5.165; χ2(1) = 5.223, p =.022). This model correctly classified 75.3% 
of the cases, but only accounted for 9.8% of the variance in the dependent variable. 
 Questions relating to insulin exposure were added in block two. These questions 
included whether or not insulin therapy was discussed at diagnosis as a potential therapy 
to treat T2DM, insulin therapy was ever discussed during treatment, the participant had a 
family member with diabetes, and the participant had a friend or family member who 
used insulin therapy. Regression results in this block indicated that the model fit of five 
variables (average serum glucose, insulin discussed at diagnosis, insulin ever discussed, 
family member with diabetes, and having a friend or family member using insulin) was 
statistically reliable in distinguishing between high and low readiness to begin insulin 
therapy (-2 Log Likelihood = 76.899, Goodness-of-Fit = 3.996; χ2(5) = 12.456, p =.029). 
This model correctly classified only 69.9% of cases, but accounted for 22.2% of the 
variance in the dependent variable (readiness).  
 In the final block, after accounting for all other covariates and confounding 
variables, the predictor variables of specific interest (PCDS total score, HCCQ total 
score, ITAS total score, and RAI score) were regressed on the dependent variable. The 
resulting overall model of six variables (average serum glucose, insulin discussed at 
diagnosis, insulin ever discussed, family member with diabetes, friend or family member 
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using insulin, and ITAS total score) was statistically reliable in distinguishing between 
high and low readiness to begin insulin therapy (-2 Log Likelihood = 69.060, Goodness-
of-Fit = 4.118; χ2(6) = 20.295, p =.002). This model correctly classified 79.5% of cases 
and accounted for 34.4% of the variance in the dependent variable. Results of the final 
bivariate logistic regression model are described in table 4.4. 
 Findings revealed that participants were 5.5 times more likely to rate readiness to 
initiate insulin therapy as high if they had a friend or family member who used insulin for 
his or her T2DM (p =.020) compared to those who had neither. In addition, for every unit 
increase in ITAS total score, participants were 8.4% more likely to rate their readiness to 
initiate insulin therapy as low (p =.012).  
Discussion 
 The objective of this study was to use Self-Determination Theory as a framework 
for identifying modifiable predictors of readiness to initiate insulin therapy when oral 
medications fail to control hyperglycemia in patients with T2DM. Specifically, the aim 
was to determine if perceived autonomy-support (HCCQ_total), perceived diabetes 
competence (PCDS_total), motivation orientation (RAI_score), and appraisal of insulin 
therapy (ITAS_total) were predictors of readiness to initiate insulin therapy in persons 
with T2DM when oral therapy fails to control hyperglycemia.     
 In this investigation ITAS total score was the only significant modifiable 
predictor of insulin readiness, although the odds ratio for this predictor was fairly small. 
This finding supported previous research that has shown the ITAS to be a valid and 
reliable measure of insulin beliefs and attitudes in patients with T2DM that affect 
patients’ perceptions of barriers to insulin use (Hermanns, et al., 2010; Makine et al., 
2009; Snoek et al., 2007).    
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 Results of the study also showed that participants who had a friend or family 
member were more than five times as likely to rate their readiness to initiate insulin 
therapy as high, but this variable is not considered a modifiable predictor of insulin 
readiness. Exposure to insulin therapy in this way may represent a subjective norm for 
those participants, suggesting that insulin therapy is an eventuality in the treatment of 
one’s T2DM. Further investigation of the mechanism through which this variable exerts 
its effect on readiness to initiate insulin is warranted. The remaining three insulin 
exposure questions remained in the final regression model but were not significant 
predictors of insulin readiness. 
 PCDS total scores were not found to predict readiness to initiate insulin therapy. 
The mean PCDS score for the study sample was very high. High scores would suggest 
that participants held high levels of competence in performing their diabetes self-care, 
which should correspondingly translate to lower average serum glucose levels which has 
been demonstrated in previous studies (Kirchbaum et al., 2003; Williams et al., 1998, 
2004, 2009), but was not supported in this study. Mean HbA1c for this sample was 
substantially higher than the ADA (2009) recommendations for target HbA1c goal.  
 Mean HCCQ score for the study sample suggests that most participants perceived 
an autonomy-supportive environment during visits with their diabetes care provider. 
Despite this finding, perceived autonomy support did not predict readiness to initiate 
insulin therapy as it had predicted engagement in diabetes self-care practices and 
glycemic control in earlier studies (Williams et al., 1998, 2004, 2009). The HCCQ not 
only evaluates dimensions of shared decision-making, patient satisfaction, and the 
diabetes provider’s respect of the patient and his or her opinions regarding treatment 
decisions, but also evaluates the patient’s trust in their provider. The high mean HCCQ 
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score in this sample was an unexpected finding given the high proportion of African 
American participants in this study combined with the knowledge that all of the diabetes 
care providers were Caucasian. Previous studies have found that African American 
patients regularly report fewer participatory visits with physicians, fewer transparent 
signs of respect, less trust, and less satisfaction with their care when racial discordance 
exists between patient and healthcare provider (Cooper-Patrick, Gallo, Gonzales, Vu, 
Powe et al., 1999; Doescher, Saver, Franks & Fiscella, 2000; LaVeist & Nuru-Jeter, 
2002).  
 RAI mean score computed by subtracting the average controlled regulation 
subscale scores from the average autonomous regulation subscale scores of the TSRQ in 
the sample yielded a negative number, indicating a tendency among participants to have a 
comparatively greater extrinsic motivation orientation. Mean RAI score did not predict 
readiness to initiate insulin therapy as it had predicted diabetes self-care practices and 
glycemic control in earlier studies (Williams, Freedman & Deci, 1998; Williams et al., 
1998). 
 One’s initial impression may be that the study’s results did not support the use of 
SDT as a framework for identifying predictors of readiness to initiate insulin therapy in 
T2DM, but it would be premature to discard this theory on the findings of a single study. 
A deeper analysis of the study’s data provides evidence to support the use of SDT as a 
framework in future studies. The HCCQ scores from the study reflect a prevailing 
autonomy-supportive clinical environment in which the study participants receive their 
diabetes care, which may explain the large number of patients who rated their readiness 
to begin insulin therapy as high. Autonomy-support has been identified as a critical 
component of SDT that promotes increased competence in performing a behavior as well 
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as increasing patients’ feelings of relatedness to a behavior (Ryan & Deci, 2000; Heisler 
et al., 2007; Williams et al., 2004). Likewise, the ceiling effect seen in mean PCDS score 
for the study sample may also have been influenced by the preponderance of autonomy-
support participants perceived from their providers in the clinical setting in which the 
study took place (Heisler et al.; Williams et al., 2004).  
 Although PCDS scores did not exhibit an inverse relationship to average serum 
glucose levels in the sample as expected, this finding does not necessarily insinuate that 
patients in the study lacked diabetes self-care competence. An alternative explanation 
might be that patients in the sample were indeed competent in performing the treatments 
prescribed by their physicians; but the treatments their physicians prescribed were 
inappropriate given the severity of their T2DM. In support of this argument, the majority 
of study participants rated their readiness to initiate insulin therapy as high (≤ 3 months) 
and nearly 60% were ready to do so immediately. Further analysis of a subgroup of 31 
patients in the sample who were both taking a single oral medication for their T2DM and 
who rated their readiness to begin insulin therapy as immediate (0 months) comprised 
43% of the total study sample; despite documented HbA1c values in the records of these 
31 patients confirming the presence of persistent hyperglycemia during the preceding six 
months (mean serum glucose = 170mg/dl ± 38).  This study’s findings confirmed 
previously reported problems of clinical inertia among diabetes care providers in primary 
care settings (Parchman, Pugh, Romero & Bowers, 2007; Peyrot et al., 2005; Ziemer et 
al., 2005). Testing SDT with more demographically diverse populations of patients and 
larger samples may support the theory’s usefulness for predicting readiness to initiate 
insulin in T2DM. 
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Limitations 
 There are a number of limitations to this study, therefore results should be 
interpreted with caution. First, even though a large number of participants expressed 
readiness to initiate insulin therapy immediately or within three months, a person’s 
expressed intention to adopt a behavior and actually doing so may not correlate well with 
one another, especially when the behavior requires a series of complicated steps, such as 
using insulin (Harvey & Lawson, 2009). The cross-sectional design employed in this 
study does not allow for evaluation of actual versus planned insulin therapy adoption by 
subjects. A prospective design that follows patients from expressed intent to start insulin 
therapy and forward would be better suited to analyze this relationship. Second, the 
sample in this study was predominantly older, female, poorer, and African American, so 
findings may not be generalizeable to populations of patients who do not share these 
characteristics. A larger and more demographically diverse sample may have yielded a 
significantly different final regression model. Third, although the psychometric 
instruments (PCDS, HCCQ, and TSRQ) used in this study have been demonstrated to be 
valid and reliable measures of the major constructs of SDT in previous studies, they have 
not been extensively tested in patients with T2DM regarding self-care practices, 
particularly with regard to insulin therapy. Further testing in this population of patients is 
necessary to determine their usefulness in explaining and predicting self-care behaviors 
in T2DM.  
Implications for Practice and Future Research 
 The significant influence of friends’ and family members’ use of insulin had on 
participant’s perceived readiness to initiate insulin therapy can be used by clinicians to 
identify patients who may be targeted for early adoption of insulin. Simply asking the 
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question at the time of diagnosis would identify these patients. A related finding from 
previous research showed that reciprocal peer support among type 2 diabetics 
significantly increased rates of insulin initiation or intensification of insulin therapy; 
suggesting that an individual’s concerns about insulin are most effectively addressed by 
other individuals coping personally with insulin management (Heisler, Vijan, Makki & 
Piette, 2010). Further understanding of the mechanism behind the influence of friends 
and family on readiness to initiate insulin may guide diabetes clinicians and researchers 
in designing prospective randomized trials that evaluate interventions which capitalize on 
this influence.  
 This study confirmed that diabetes treatment intensification is not occurring 
despite the presence of documented chronic hyperglycemia, even though HbA1c goals 
and therapy intensification guidelines are readily available to clinicians (Nathan et al., 
2006). A large majority of participants in this study indicated high levels of readiness to 
initiate insulin therapy but only about half of them recalled having a conversation about 
insulin with their doctor.  Discussions of insulin’s role in the treatment of T2DM must 
occur with patients at the time of diagnosis and continue throughout the course of 
treatment. Research investigating diabetes care models that reduce or eliminate clinical 
inertia are still needed.  
 Finally, more research testing SDT as a framework for understanding diabetes 
self-care practices, especially insulin therapy, will be needed in the future. This study was 
unable to show that perceived autonomy support, motivation orientation, and perceived 
diabetes competence were significant predictors of readiness to initiate insulin therapy. 
This theoretical framework holds promise for testing innovative models of diabetes care 
that respect the self-agency of people with T2DM.  
 81 
 
Summary and Conclusion 
 This study adds to the body of literature in a number of ways. Findings support 
prior research that insulin beliefs and attitudes affect type 2 diabetics’ perceptions 
regarding insulin therapy. This study provides further evidence that negative beliefs and 
attitudes toward insulin predict lower readiness to initiate insulin therapy. Study findings 
also suggest that patients who have friends or family members using insulin therapy are 
significantly more likely to adopt insulin therapy sooner when oral antidiabetic agents are 
unable to control their hyperglycemia. Further evidence that clinical inertia exists in 
primary care was presented by this study, even when patients indicated that they were 
ready to begin insulin immediately as this study’s findings demonstrated. This research 
also supported previous study findings that insulin is often not discussed by diabetes care 
providers as an eventual therapy for treating T2DM at the time of diagnosis, nor is it 
routinely discussed at any time during treatment even though patients’ HbA1c is not at 
goal. Finally, findings from this study provided conflicting evidence from prior research 
regarding racial discordance between patients and providers. Findings from this research 
revealed that patients trusted their diabetes care providers, felt respected by them, were 
satisfied with the care they received, and shared in decision-making about their treatment, 
despite the presence of racial discordance between patients and providers. 
  Substantial morbidity and mortality result from the mismanagement of T2DM in 
the current diabetes care model; much of it preventable with the institution of timely 
interventions. Given the rapidly escalating incidence and wide prevalence of T2DM, the 
model of care must change if there is to be hope for improving diabetes outcomes as well 
as the health and quality of life of the population as a whole.  
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Table 4.1 Demographic Characteristics 
 
Variable   Mean (±SD)  Frequency (%) Range 
 
 
Age (years)           57.3 (11.9)       22 – 81 
Education (years)          11.0 (2.1)              8 – 16 
Race    
     African American             52 (71) 
     Caucasian              20 (27.5) 
     Latino        1 (1.5) 
Gender           
     Male              22 (30) 
     Female      51 (70) 
Cohabitation 
     Lives alone      34 (47) 
     Lives with someone    39 (53) 
Income 
     < $30,000/year     56 (77) 
     ≥ $30,000/year < $60,000/year   13 (18) 
     > $60,000/year       4 (5) 
________________________________________________________________________ 
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Table 4.2 Clinical Characteristics and Exposure to Insulin 
 
Variable    Mean (±SD)    Frequency (%) Range 
 
 
Average Serum glucose (mg/dl) 202.9 (65.3)    104 – 441 
Duration of diabetes (years)      6.5 (5.8)     0.5 – 25 
Years with current doctor      5.3 (5.6)     0.5 – 21 
 
Number of oral diabetes medications 
     One           43 (59) 
     Two           20 (27.5) 
     Three             9 (12) 
     Four             1 (1.5) 
 
Insurance status  
     None (self-pay)          11 (15) 
     Public (Medicaid/Medicare)        41 (56) 
     Private            21 (29) 
 
Insulin discussed w/MD at diagnosis 
     Yes            35 (48) 
     No            38 (52) 
Insulin ever discussed w/MD 
     Yes            35 (48) 
     No            38 (52) 
Family member with diabetes 
     Yes            50 (68.5) 
     No            23 (31.5) 
Friend or family member uses insulin 
     Yes            35 (48) 
     No            38 (52) 
________________________________________________________________________ 
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Table 4.3 Psychometric Measurement Scores 
 
Variable  Mean (± SD)  Minimum Maximum Range 
 
 
Total PCDS  23.6 (5.2)        4        28     24 
Total HCCQ  96.9 (10.5)       39      105     66 
Total ITAS  57.3 (11.7)       56        83     56 
RAI   - 2.3 (20.1)      -88        72   160 
________________________________________________________________________ 
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Table 4.4 Final Logistic Regression Model  
 
Variable       β  Wald   df   p       OR 
 
 
Avg. serum glucose     .009  3.436      1 .064      1.009 
Insulin discussed at diagnosis  - .877  1.529    1 .216         .416 
Insulin ever discussed   - .581  .694    1 .405         .559 
Family member with T2DM  - .989  1.880    1 .170         .372 
Friend/family member uses insulin 1.698  5.373    1 .020       5.461 
ITAS total score     .081  6.312    1 .012       1.084 
Constant               -7.541            11.346    1 .001         .001 
________________________________________________________________________ 
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CHAPTER FIVE 
Discussion, Implications, and Future Research 
 Type 2 diabetes is a significant public health problem that has reached epidemic 
levels both in the U.S. and globally (National Diabetes Information Clearinghouse 
[NDIC], 2011; Wild, Roglic, Green, Sicree & King, 2004). Nearly 26 million Americans 
are diagnosed with diabetes, 90 to 95% of which are type 2 diabetes (T2DM). People 
with T2DM are two to four times more likely to have a stroke or die from heart disease 
than are people without diabetes. In addition, they are twice as likely to suffer clinical 
depression than someone without diabetes (NDIC). The NDIC recently estimated direct 
costs from T2DM are $116 billion and indirect costs are $58 billion annually. These costs 
are projected to exceed well over $300 billion by 2034 (Huang, Basu, O’Grady & 
Capretta, 2009). 
 Published evidence-based diabetes care guidelines clearly delineate the process 
and outcome criteria for effectively managing diabetes care to prevent unnecessary 
morbidity and mortality in T2DM (American Diabetes Association [ADA], 2011). Target 
HbA1c level and the means by which to achieve glycemic goal have been identified and 
extensively communicated to clinicians through the National Diabetes Education 
Program (2009) targeting all health care providers who manage T2DM care. Despite a 
number of effective medications and clear guidelines explicating their use in the clinical 
management of T2DM, barely half of type 2 diabetics ever achieve recommended HbA1c 
goals (Cobble, 2009).  
 The current paradigm of diabetes care within the U.S. healthcare system has 
demonstrated inadequacy for achieving optimal patient outcomes in T2DM (Anderson & 
Funnell, 2005; Brown, Nichols & Perry, 2004; Grant, Buse & Meigs, 2005; Heisler, 
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Bouknight, Hayward, Smith & Kerr, 2002; Perlin & Pogach, 2006). Chronic uncontrolled 
hyperglycemia that results as a consequence of failure to appropriately manage patients’ 
T2DM causes serious and debilitating sequelae that diminish patients’ health-related 
quality of life (HRQOL) and place them at risk for premature death (NDIC, 2011).  
 In this dissertation, three manuscripts were presented to provide an initial 
understanding to the problem of T2DM and problems with its current clinical 
management in the U.S. The chapters of this dissertation critically reviewed the available 
literature regarding clinical inertia in primary healthcare providers managing T2DM, 
described the development of a conceptual model to explain and predict readiness of 
patients with T2DM to initiate insulin therapy, and reported findings from a study that 
investigated predictors of readiness to initiate insulin therapy in patients with T2DM 
when oral agents fail to control hyperglycemia using the conceptual model as a 
framework for this study.  
 In Chapter Two, the available literature regarding clinical inertia was reviewed 
and analyzed. Four themes emerged from the analysis to explain reasons for clinical 
inertia in management of T2DM in primary care: (1) competing demands in primary care, 
(2) lack of training and failure to follow published guidelines, (3) physician attitudes and 
patient noncompliance, and (4) physicians’ misconceptions of patient barriers to insulin 
therapy.  
 The health care problems experienced by most diabetic patients treated in primary 
care place multiple competing demands on a clinician’s time and attention (Parchman, 
Pugh, Romero & Bowers, 2007; Ziemer et al., 2005). It is unlikely that this situation will 
improve under the current paradigm of diabetes care (Anderson & Funnell, 2005; Reach, 
2008). However, research testing novel collaborative care models described in the 
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integrative review show promise for improving the pressure primary care clinicians 
experience while improving outcomes for their diabetic patients (Graber, Elasy, Quinn, 
Wolff & Brown, 2002; Phillips et al., 2005). Research efforts to develop and test novel 
collaborative care models must continue. 
 Lack of sufficient training and failure to follow published diabetes guidelines is a 
pervasive problem in the U.S. as demonstrated by a number of previous studies 
(Benjamin, Schneider & Hinchey, 1999; Fleming et al., 2001; Giangola, Olahan, Longo, 
Goldstein & Gross, 2008; Grant, Buse & Meigs, 2005; Perlin & Pogach, 2006; Riddle, 
2002). Several researchers have designed studies to evaluate various methods for 
integrating evidence into practice environments in a variety of settings using HbA1c as 
the clinical evaluation endpoint (Aubert, Herman, Waters, Moore, Sutton, et al., 1998; de 
Sonnaville, Bouma, Colly, Deville, Wijkel & Heine, 1997). All of the studies reported 
modest yet significant reduction in participants’ HbA1c values (p = .001 to .02), though 
none of the interventions were able to bring a majority of participants’ HbA1c levels to 
ADA goal (< 7%). Further methods for integrating evidence into practice will need to be 
developed and tested, especially prospective, longitudinal studies to evaluate effects on 
practices over time. 
 Physicians’ attitudes towards patients’ nonadherence to therapy, whether real or 
imagined, was a major reason for clinical inertia identified in the literature. (Drass et al., 
1998; Grant et al., 2007; Larme & Pugh, 1998; Peyrot et al., 2005). Poor attitudes toward 
patient nonadherence adversely affected a physician’s tendency to intensify a patient’s 
diabetic therapy, particularly so with initiation of insulin therapy. Autonomy-supportive 
clinical environments that respect the self-agency of patients will need to be developed 
for effective engagement of patients in their care.  
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 Finally, misconceptions on the part of physicians regarding patients’ perceived 
barriers and fears about insulin versus actual barriers and fears identified by patients 
played a significant role in physicians’ reluctance or failure to prescribe insulin therapy 
when patients’ clinical disease warranted doing so (Nakar, Yitzhaki, Rosenberg & 
Vinker, 2007). The ITAS is a valid and reliable instrument for measuring patients’ beliefs 
and attitudes regarding insulin therapy and it needs to be used consistently by clinicians 
to determine what patients’ actual feelings are. 
 In Chapter Three, behavioral theories, namely social cognition theories, were 
critically analyzed to determine their appropriateness for use as an underpinning 
theoretical framework for investigating predictors of readiness to initiate insulin therapy 
in patients with T2DM. Conceptual framing for many of the health behavior models and 
theories reviewed were very similar and their constructs are deeply intertwined (Conner 
& Norman, 2005; Rothman, 2000). Models and theories considered were the Health 
Belief Model (Rosenstock, Strecher & Becker, 1988), the Theory of Planned Behavior 
(Azjen, 1991; 2002), Social Cognitive Theory (Bandura, 1977; 1982; 2001), and Self-
determination Theory (Deci & Ryan, 2000).  
 Although widely used in many studies attempting to understand health behaviors, 
the ability of the Health Belief Model (HBM) to explain the variance in diabetes regimen 
adherence and glycemic control in studies of type 2 diabetes were found to be 
inconsistent and disappointing (Harvey & Lawson, 2009). Researchers observed no 
relationship between health beliefs and adherence, health beliefs and HbA1c levels, or 
adherence and HbA1c levels (Woolridge, Wallston, Graber, Brown & Davidson, 1992).  
Because of the asymptomatic nature of T2DM during the first several years of the 
disease, the two major tenets related to individuals’ representations of health proposed by 
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the HBM, perceptions of illness threat and evaluation of methods to counteract this 
threat, are typically absent until symptoms have appeared and diabetes is quite advanced 
(Conner & Norman, 2005). Absence of perceived threat may translate into a lack of 
perceived benefits regarding necessary lifestyle changes, self-care practices, and 
treatment intensification to maintain glycemic control until an individual’s diabetes is 
more advanced and overtly symptomatic, making it a poor choice to predict insulin 
readiness (Dietrich, 1996). 
 The Theory of Planned Behavior (TPB), an extension of the Theory of Reasoned 
Action (TRA), contends that proximal determinants of behavior include intention to 
engage in the behavior and perception that one has control over the behavior (Azjen, 
1991; 2002). Only a single study using type 1 diabetics (n = 64) employing a TPB-based 
model to predict adherence to blood glucose monitoring was found (Shankar, Conner & 
Bodansky, 2007). Although a substantial amount of the variance (57%) in subjects 
maintaining self-monitoring of their blood glucose was explained by this model, it is a 
relatively simple maintenance behavior compared to complexity of the behaviors and 
skills needed for competent use of insulin in T2DM. In addition, stated intention to act 
does not always result in action being taken as many clinicians know first-hand.  
 Social Cognitive Theory (SCT) (Bandura, 1977; 1982; 2001) was most frequently 
used in studies of diabetes self-care behavior. One of the theory’s major constructs, self-
efficacy (SE), which represents the belief that a behavior or action is or is not under the 
individual’s control, has served as a conceptual framework for multiple behavioral 
intervention studies related to self-care in type 2 diabetes; termed diabetes self-efficacy 
(DSE) (Anderson et al., 1995; Anderson & Funnell, 2000; Anderson, Funnell, Fitzgerald 
& Marrero, 2000; Anderson et al., 2009; Cherrington, Wallston & Rothman, 2010; 
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Wallston, Rothman & Cherrington, 2007). Studies reviewed have supported DSE as an 
important predictor of routine diabetes self-care, but it has not been specifically tested as 
a predictor of readiness to initiate insulin therapy. In addition, the concept of DSE alone 
does not fully encompass the myriad influences and processes by which diabetes self-care 
practices are incorporated into one’s behavioral repertoire. 
 The major premise of Self-Determination Theory (SDT) posits that humans are 
motivated toward physical and psychological health (Ryan & Deci, 2000). Although SDT 
and SCT share similarities, SDT appears to consider a more global approach to 
understanding adoption of behaviors, particularly when it has used as the theoretical 
framework for studying the adoption and maintenance of self-care behaviors in T2DM 
(Heisler et al., 2002; Williams, Freedman & Deci, 1998; Williams, McGregor, Zelman, 
Freedman & Deci, 2004; Williams et al., 2009; Williams, Rodin, Ryan, Grolnick & Deci, 
1998). The conceptual model based on SDT presented in Chapter Three illustrates the 
multiple influences that impact both patients and providers as they come together to form 
shared goals, changing the current paradigm to reflect and value human self-agency 
(Heisler et al., 2002). 
 In Chapter Four, findings from a descriptive correlational study of predictors of 
readiness to initiate insulin therapy in patients with type 2 diabetes are reported. The 
objective of this study was to use SDT as a framework to identify modifiable predictors 
of readiness to initiate insulin therapy when oral medications fail to control 
hyperglycemia in patients with T2DM. Specifically, the aim was to determine if 
perceived autonomy-support, perceived diabetes competence, motivational orientation, 
and appraisal of insulin therapy were predictors of readiness to initiate insulin therapy in 
persons with T2DM when oral therapy fails to control hyperglycemia. Significant 
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predictors of readiness to initiate insulin therapy in patients with T2DM were attitudes 
and beliefs about insulin (p =.012) measured by the Insulin Therapy Appraisal Scale 
(ITAS total score) and whether or not participants had a friend or family member that 
used insulin (p =.020). The odds of a participant rating readiness to initiate insulin 
therapy as high were 5.5 times more likely if that participant had a friend or family 
member who used insulin for his or her T2DM compared to those who had neither. In 
addition, for every unit increase in ITAS total score, participants were 8.4% more likely 
to rate their readiness to initiate insulin therapy as low. This finding confirms results from 
previous studies using the ITAS as a measure of beliefs and attitudes toward insulin. 
 The study also found that most participants rated their readiness to initiate insulin 
therapy as high and nearly 60% stated they would begin insulin immediately if it would 
control their hyperglycemia. However, the study sample’s mean HbA1c was 8.7% over 
the preceding six months of the study, a finding that supported previous studies’ findings 
that appropriate intensification of diabetes therapy in the presence of documented chronic 
hyperglycemia is not occurring in primary care settings. 
 Although the autonomy-support, motivation orientation, and perceived 
competence were not found to be significant predictors of readiness to initiate insulin, 
SDT is still an appropriate theoretical framework for future study of this phenomenon 
within a diabetes care paradigm that respects self-agency. This is only the first study 
using SDT in the context of understanding what increases the readiness of type 2 
diabetics to begin insulin therapy. Further study is recommended.  
 The current mode of diabetes management in primary care cannot continue. The 
human misery, healthcare costs, and disability caused by clinical inertia are un-
conscionable. Clinicians have effective pharmacotherapeutic tools and cutting-edge 
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science that have been demonstrated to be powerful in achieving the best outcomes in 
T2DM. Future research must target interventions that put these powerful tools into action. 
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